Note: Descriptions are shown in the official language in which they were submitted.
CA 02626558 2010-03-25
PHARMACEUTICAL COMPOSITION HAVING
REDUCED ABUSE POTENTIAL
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition
comprising a controlled release agent. The present invention also relates to
the use and method for making the same.
BACKGROUND OF THE INVENTION
Drug abuse has almost become a way of life to a rapidly growing
segment of the world population, for example in the United States and
Canada. It has become the vogue of many of the younger generation to
experiment with any type of drug that will produce an emotional,
psychological, euphoric, depressive or generally psychedelic experience.
A major problem is the abuse of medicinal opioid formulations by the
parenteral route.
Another route of abuse which has become of serious concern is
snorting of fine powder obtained from crushed opiod dosage form or the oral
ingestion of finely crushed extended release oral dosage form in order to
instantaneously obtain the benefit of the total opiod present in the slow
release dosage form.
Another phenomenon that has become of concern regarding the use of
extended release opiod analgesics is the discovery that they dose dump in
the presence of alcohol and release all their content at once.
There has been a lot of concern with regards to the performance of
extended release narcortics taught in prior art and currently commercialized.
This is because the extended release or controlled release mechanism of
current extended release opiod agonists using compositions and methods
taught in the prior art is compromised and destroyed in the presence of
-1-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
alcohol leading to the loss of controlled release effects and complete release
or dose dumping of its opiod content.
The danger and economic consequences of dose dumping in the
presence of alcohol for current controlled release narcotic analgesics was
highlighted when in July 14, 2005 Purdue Pharma voluntarily took its pain-
relieving narcotic analgesic Palladone (hydromorphone hydrochloride)
capsules off the market. The company took the action on July 13 following an
FDA request to withdraw Palladone because of safety concerns. The FDA
approved Palladone in September 2004. The drug was launched by Purdue
Pharma in February 2005. Palladone was approved for the management of
persistent, moderate-to-severe pain in patients requiring continuous, around-
the-clock pain relief with a high-potency opioid for an extended period of
time.
An FDA news release stated that serious and potentially fatal adverse
reactions can occur when Palladone extended release capsules are taken
together with alcohol.
According to an FDA news release, Palladone is a once-a-day pain
management drug containing a very potent narcotic. New data gathered from
a company-sponsored study testing the potential effects of alcohol use shows
that when Palladone is taken with alcohol the extended release mechanism is
harmed which can lead to dose-dumping. The FDA described dose-dumping,
as the rapid release of the drug's active ingredient into the bloodstream. The
agency's news release pointed out that dose-dumping, even with a low dose
of Palladone (12 milligrams), could lead to "serious, or even fatal, adverse
events in some patients". The FDA also warned that the risk increases for
higher doses of Palladone.
Health Canada also issued an Advisory to warn of serious health risks
associated with the consumption of alcohol while taking any slow-release
opioid analgesics, following data from Purdue Pharma.
It can be argued that just like in the case of Palladone all powerful pain
management drugs such as opiod agonists or narcotic analgesics have
serious risks if used incorrectly, and this is particularly true for the
current
extended release formulations in the prior art or under commercialization. In
-2-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
fact Health Canada has advised patients receiving other slow-release opioids
to be aware that these products may react in a similar way to hydromorphone
slow release formulation when co-ingested with alcohol i.e., they may be
released into the blood quickly (dose-dumping) instead of over extended
release time periods, for example 24 hours.
This situation continues to present an unacceptably high level of
patient risk. There is a great concern that as more patients take current
compostions, safety problems will arise since even having one alcoholic drink
could have fatal implications. The use of patient information vial label
warnings regarding the dangers of using opioids and alcohol concomitantly is
not expected to solve this problem. As a matter of fact the FDA has said that
the agency doesn't believe that "potentially fatal, adverse events can be
effectively managed by label warnings alone. ..."
Health authourities have turned up the heat and are demanding the
pharmaceutical companies come clean and put interests of patients first.
Accordingly, to investigate if the same effect occurs with other slow-release
drugs, Health Canada requests that all manufacturers of these products
provide information on the interaction between their drug and alcohol; if this
is
not possible, studies investigating product interactions with alcohol are to
be
conducted and completed within six months. Health Canada states that the
data will be assessed within a three-month period and that further action will
be taken if required.
From the foregoing there is therefore an urgent and great need for
compositions of opiod agonist or narcotic analgesics or abuse-able
substances which have a reduced potential for abuse or dose-dumping in the
presence of alcohol.
Attempts have been made in the past to control the abuse potential
associated with opioid analgesics. Parenteral dose of opioid analgesics are
more potent as compared to the same dose administered orally. Therefore,
drug abuse is often carried out by the extraction of the opioid from the
dosage
form, and the subsequent injection of the opioid (using any "suitable" vehicle
for injection) in order to achieve a "high." Attempts to curtail abuse have
-3-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
therefore typically centered around the inclusion in the oral dosage form of
an
opioid antagonist which is not orally active but which will substantially
block
the analgesic effects of the opioid if one attempts to dissolve the opioid and
administer it parenterally.
U.S. Pat. No. 3,254,088, describes the preparation of naloxone and its
activity as a narcotic antagonist.
U.S. Pat. No. 3,493,657, describes the combination of morphine and
naloxone as a composition for parenteral use "which has a strong analgesic,
as well as antagonistic effect, without the occurrence of undesired or
dangerous side effects."
A New York Times article appearing in a July 14, 1970 issue described
the oral administration of naloxone to narcotic addicts as a method of
treatment. The oral administration of naloxone (in high doses) "makes it
impossible for the addict to experience a high no matter how much heroin he
uses."
The combination of pentazocine and naloxone has been utilized in
tablets available in the United States, commercially available as Talwin from
Sanofi-Winthrop. Talwin contains pentazocine hydrochloride equivalent to
50 mg base and naloxone hydrochloride equivalent to 0.5 mg base. Talwin
is indicated for the relief of moderate to severe pain. The amount of naloxone
present in this combination has no action when taken orally, and will not
interfere with the pharmacologic action of pentazocine. However, this amount
of naloxone given by injection has profound antagonistic action to narcotic
analgesics. Thus, the inclusion of naloxone is intended to curb a form of
abuse of oral pentazocine which occurs when the dosage form is solubilized
and injected. Therefore, this dosage has lower potential for parenteral abuse
than previous oral pentazocine formulations. However, it is still subject to
patient misuse and abuse by the oral route, for example, by the patient taking
multiple doses at once.
Sunshine, et al. "Analgesic Efficacy of Pentazocine Versus a
Pentazocine-Naloxone Combination Following Oral Administration", Clin. J.
Pain, 1988:4:35-40, reported on the effect of the addition of 0.5 mg naloxone
-4-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
on the analgesic efficacy of pentazocine 50 mg. The combination was found
to be significantly less efficacious than pentazocine for the sum of the pain
intensity difference (SPID), and for relief and pain intensity difference
(PID) at
the fourth hour. For patients with moderate baseline pain, the combination
produced significantly less pain relief than pentazocine for SPID and for
relief
and PID at hours 3 and 4. In patients with severe baseline pain, there was no
significant difference found between pentazocine and the combination of
pentazocine plus naloxone.
Wang, et al. "Crossover and Parallel Study of Oral Analgesics", J. Clin
Pharmacol 1981; 21:162-8, studied the combination of naloxone 0.25 mg and
Percodan (composed of 4.5 mg oxycodone HC1, oxycodone terephthalate
0.28 mg, aspirin 224 mg, phenacetin 160 mg, and caffeine 32 mg) compared
to Percodan alone, and placebo in a crossover study of patients with chronic
pain. The combination had lower mean scores than Percodan alone for most
of the analgesic hourly parameters in the later hours of the trial. However,
for
the summary variables, the combination showed no significant difference from
either placebo or Percodan .
A fixed combination of buprenorphine and naloxone was introduced in
1991 in New Zealand (Temgesic , Reckitt & Colman) for the treatment of
pain.
A fixed combination therapy comprising tilidine (50 mg) and naloxone
(4 mg) has been available in Germany for the management of severe pain
since 1978 (Valoron , Goedecke). The rationale for the combination of these
drugs is effective pain relief and the prevention of tilidine addiction
through
naloxone-induced antagonisms at the morphine receptor.
U.S. Pat. No. 3,773,955 (Pachter, et al.) described orally effective
analgesic compositions which upon parenteral administration do not produce
analgesia, euphoria, or physical dependence, and thereby prevent parenteral
abuse of the analgetic agents. Such compositions contained from about 0.1
mg to about 10 mg naloxone per analgetic oral dose. This reference was not
concerned with oral abuse of opioids.
-5-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
U.S. Pat. No. 3,493,657 (Lewenstein, et al.) described compositions
comprising naloxone and morphine or oxymorphone, which compositions
were said to provide a strong analgesic effect without the occurrence of
undesired side effects such as hallucinations.
U.S. Pat. No. 4,457,933 (Gordon, et al.) described a method for
decreasing both the oral and parenteral abuse potential of strong analgesic
agents such as oxycodone, propoxyphene and pentazocine, by combining an
analgesic dose of the opioid with naloxone in a specific, relatively narrow
range. Oxycodone-naloxone compositions having a ratio of 2.5-5:1 parts by
weight and pentazocine-naloxone compositions having a ratio of 16-50:1 parts
by weight were preferred. The dose of naloxone which was to be combined
with the opioid is stated to substantially eliminate the possibility of either
oral
or parenteral abuse of the opioid without substantially affecting the oral
analgesic activity thereof.
U.S. Pat. No. 4,582,835 (Lewis) describes a method of treating pain by
administering a sublingually effective dose of buprenorphine with naloxone.
Lewis describes dosage ratios of naloxone to buprenorphine from 1:3 to 1:1
for parenteral administration, and from 1:2 to 2:1 for sublingual
administration.
U.S. Pat. No. 6,627,635 teaches a method of preventing abuse of
opioid dosage forms wherein an analgesically effective amount of an orally
active opioid agonist is combined with an opioid antagonist into an oral
dosage form which would require at least a two-step extraction process to be
separated from the opioid agonist, the amount of opioid antagonist including
being sufficient to counteract opioid effects if extracted together with the
opioid agonist and administered parenterally.
U.S. Pat. 6,696,088 discloses tamper-resistant oral opioid agonist
formulations comprising (i) an opioid agonist in releasable form and (ii) a
sequestered opioid antagonist which is substantially not released when the
dosage form is administered intact, such that the ratio of the amount of
antagonist released from said dosage form after tampering to the amount of
said antagonist released from said intact dosage form is about 4:1 or greater,
-6-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
wherein said agonist and antagonist are interdispersed and are not isolated
from each other in two distinct layers.
Despite all the above attempts in the prior art to address the problem of
drug abuse, the problem persists partly because of design faults in the
compositions and the addicts coming up with creative ways to beat the anti
drug abuse mechanism. At present the problem is escalating at an alarming
rate with devastating financial and social consequences.
Therefore, there is still a need to develop a stable drug delivery device
that can be reproducibly manufactured and have a desired effect of reducing
potential for abuse.
SUMMARY OF THE INVENTION
An object of one aspect of the present invention is to provide a
composition that can be effectively employed to control the release of an
active substance.
An object of a second aspect of the present invention is to provide a
composition that can be effectively employed to reduce the problem of dose
dumping of an active substance.
An object of a third aspect of the present invention is to provide a
composition that can be effectively employed to reduce the potential for abuse
of an active substance.
In accordance with an aspect of the present invention, there is provided
a pharmaceutical paste composition comprising an active substance and
materials selected from clays, controlled release agents or oily, waxy or
fatty
substances in an amount and ratio which is sufficient to prevent the
compromising or loss of integrity of the controlled release mechanism of the
composition upon oral administration or co-ingestion with alcohol.
In accordance with another aspect of the present invention, there is
provided a means for preventing dose dumping in the presence of alcohol and
the prevention of the abuse of oral formulations of therapeutically valuable
active substances by admixing such substances with materials selected from
clays, oily, waxy or fatty substances or controlled release agents.
-7-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
In accordance with yet another aspect of the present invention, there is
provided a controlled release composition and method in which the
physicochemical nature of the composition helps to prevent dose dumping in
the presence of alcohol and also discourage abuse and make it harder to
abuse by mode of crushing, milling or grinding and dissolving, heating to
cause evaporation and snorting, "shooting" or inhalation.
In accordance with still another aspect of the present invention, there is
provided a pharmaceutical paste composition comprising: i) an active
substance; ii) an oily, waxy, or fatty substance, or a combination thereof;
and
iii) a controlled release agent; wherein the paste composition is non-
newtonian, thixotropic and/or pseudoplastic.
In accordance with still another aspect of the present invention, there is
provided a pharmaceutical paste composition comprising: i) an active
substance; ii) a controlled release agent; and iii) a non-aqueous vehicle;
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In accordance with still another aspect of the present invention, there is
provided a pharmaceutical paste composition comprising: i) an active
substance; ii) a clay; and iii) a controlled release agent; and iv) a non-
aqueous
vehicle; wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In accordance with still another aspect of the present invention, there is
provided a pharmaceutical paste composition comprising: i) an addictive
substance; ii) an oily, waxy, or fatty substance, or a combination thereof;
and
iii) a controlled release agent; wherein the paste composition is for use in a
dosage form dispensing device.
In accordance with still another aspect of the present invention, there is
provided a pharmaceutical paste composition comprising: i) an addictive
substance; ii) a controlled release agent; and iii) a non-aqueous vehicle;
wherein the paste composition is for use in a dosage form dispensing device.
In accordance with still another aspect of the present invention, there is
provided a pharmaceutical paste composition comprising: i) an addictive
-8-
CA 02626558 2011-01-31
substance; ii) a clay; and iii) a controlled release agent; and iv) a non-
aqueous vehicle; wherein the paste composition is for use in a dosage form
dispensing device.
In accordance with still another aspect, there is provided a
pharmaceutical paste composition comprising: i) an addictive substance; ii)
a clay; and iii) a polymeric controlled release agent; and iv) a non-aqueous
vehicle; wherein the paste composition is for use in a dosage form
dispensing device.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) an oily, waxy, or fatty substance, or a combination thereof;
iii) a controlled release agent; and
iv) a disintegrant,
wherein the paste composition is for use in a dosage form dispensing
device.
In a further aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) a non-aqueous vehicle;
iii) a controlled release agent; and
iv) a disintegrant
wherein the paste composition is for use in a dosage form dispensing
device.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) a clay;
iii) a polymeric controlled release agent;
iv) a non-aqueous vehicle; and
v) a disintegrant,
-9-
CA 02626558 2011-01-31
wherein the paste composition is for use in a dosage form dispensing
device.
In a further aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) an oily, waxy, or fatty substance, or a combination thereof;
iii) a controlled release agent; and
iv) a disintegrant,
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) a controlled release agent;
iii) a non-aqueous vehicle; and
iv) a disintegrant,
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In a further aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) a clay;
iii) a controlled release agent;
iv) a non-aqueous vehicle; and
v) a disintegrant,
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
-9a-
CA 02626558 2011-01-31
i) an addictive substance;
ii) an oily, waxy, or fatty substance, or a combination thereof; and
iii) a controlled release agent;
wherein the paste composition is for use in a dosage form dispensing
device, and
wherein the abuse potential of the addictive substance is reduced for at
least one of the modes of crushing, milling or grinding the dosage form to
powder and snorting or inhalation by the nasal route or dissolving for abuse
via the parenteral route.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) a non-aqueous vehicle;
iii) a controlled release agent; and
iv) a disintegrant
wherein the paste composition is for use in a dosage form dispensing
device, and
wherein the abuse potential of the addictive substance is reduced for at
least one of the modes of crushing, milling or grinding the dosage form to
powder and snorting or inhalation by the nasal route or dissolving for abuse
via the parenteral route.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) a clay;
iii) a polymeric controlled release agent; and
iv) a non-aqueous vehicle;
wherein the paste composition is for use in a dosage form dispensing
device, and
-9b-
CA 02626558 2011-01-31
wherein the abuse potential of the addictive substance is reduced for at
least one of the' modes of crushing, milling or grinding the dosage form to
powder and snorting or inhalation by the nasal route or dissolving for abuse
via the parenteral route.
In another aspect, there is provided a pharmaceutical paste
composition for use as an implant or subcutaneous application, the
composition comprising:
i) an addictive substance;
ii) an oily, waxy, or fatty substance, or a combination thereof; and
iii) a controlled release agent;
wherein the paste composition is for use in a dosage form dispensing
device.
In another aspect, there is provided a pharmaceutical paste
composition for use as an implant or subcutaneous application, the
composition comprising:
i) an addictive substance;
ii) a non-aqueous vehicle;
iii) a controlled release agent; and
iv) a disintegrant
wherein the paste composition is for use in a dosage form dispensing
device.
In another aspect, there is provided a pharmaceutical paste
composition for use as an implant or subcutaneous application, the
composition comprising:
i) an addictive substance;
ii) a clay;
iii) a polymeric controlled release agent; and
iv) a non-aqueous vehicle;
wherein the paste composition is for use in a dosage form dispensing
device.
-9c-
CA 02626558 2011-01-31
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) an oily, waxy, or fatty substance, or a combination thereof; and
iii) a controlled release agent;
wherein the paste composition is for use in a dosage form dispensing
device, and
wherein dissolution using a USP dissolution tester is not significantly
affected by the rotation speed of the basket or paddle in the speed range from
about 25 rpm to about 150 rpm.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) a non-aqueous vehicle;
iii) a controlled release agent; and
iv) a disintegrant
wherein the paste composition is for use in a dosage form dispensing
device, and
wherein dissolution using a USP dissolution tester is not significantly
affected by the rotation speed of the basket or paddle in the speed range from
about 25 rpm to about 150 rpm.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an addictive substance;
ii) a clay;
iii) a polymeric controlled release agent; and
iv) a non-aqueous vehicle;
wherein the paste composition is for use in a dosage form dispensing
device, and
-9d-
CA 02626558 2011-01-31
wherein dissolution using a USP dissolution tester is not significantly
affected by the rotation speed of the basket or paddle in the speed range from
about 25 rpm to about 150 rpm.
In another aspect, there is provided a capsule comprising a
pharmaceutical paste composition comprising:
i) an addictive substance;
ii) an oily, waxy, or fatty substance, or a combination thereof; and
iii) a controlled release agent;
wherein the paste composition is for use in a dosage form dispensing
device.
In another aspect, there is provided a capsule comprising a
pharmaceutical paste composition comprising:
i) an addictive substance;
ii) a non-aqueous vehicle;
iii) a controlled release agent; and
iv) a disintegrant
wherein the paste composition is for use in a dosage form dispensing
device.
In another aspect, there is provided a capsule comprising a
pharmaceutical paste composition comprising:
i) an addictive substance;
ii) a clay;
iii) a polymeric controlled release agent; and
iv) a non-aqueous vehicle;
wherein the paste composition is for use in a dosage form dispensing device.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) an oily, waxy, or fatty substance, or a combination thereof; and
iii) a controlled release agent;
-9e-
CA 02626558 2011-01-31
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic, and
wherein the composition is a combination of two or more paste
compositions, each paste composition comprising a different active substance
and/or having a different release profile.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) a controlled release agent; and
iii) a non-aqueous vehicle;
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic, and
wherein the composition is a combination of two or more paste
compositions, each paste composition comprising a different active substance
and/or having a different release profile.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) a clay;
iii) a controlled release agent; and
iv) a non-aqueous vehicle;
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic, and
wherein the composition is a combination of two or more paste
compositions, each paste composition comprising a different active substance
and/or having a different release profile.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) an oily, waxy, or fatty substance, or a combination thereof;
-9f-
CA 02626558 2011-01-31
iii) a controlled release agent;
v) an aqueous vehicle; and
vi) an emulsifier;
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) a controlled release agent;
iii) a non-aqueous vehicle;
v) an aqueous vehicle; and
vi) an emulsifier;
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
In another aspect, there is provided a pharmaceutical paste
composition comprising:
i) an active substance;
ii) a clay;
iii) a controlled release agent;
iv) a non-aqueous vehicle;
v) an aqueous vehicle; and
vi) an emulsifier;
wherein the paste composition is non-newtonian, thixotropic and/or
pseudoplastic.
The novel features of the present invention will become apparent to
those of skill in the art upon examination of the following detailed
description of the invention. It should be understood, however, that the
detailed description of the invention and the specific examples presented,
while indicating certain embodiments of the present invention, are
provided for illustration purposes only because various changes and
-9g-
I 4
CA 02626558 2011-01-31
modifications within the spirit and scope of the invention will become
apparent to those of skill in the art from the detailed description of the
invention and claims that follow.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings are illustrative of embodiments of the
invention and are not meant to limit the scope of the invention as
encompassed by the claims:
FIGURE 1 shows, in accordance with an embodiment of the
invention, data regarding the release of an active pharmaceutical ingredient
over a sustained-release period in varying concentrations of alcohol.
DETAILED DESCRIPTION OF THE INVENTION
Certain embodiments of the present invention relate to a novel
composition and to a method of using and preparing same in order to
reduce the potential for abuse of an addictive substance. This is
accomplished by the use of a paste composition. The addictive substance
may be, without limitation, an opiod agonist, a narcotic analgesic,
barbiturates, central nervous system stimulants, and/or tranquilizers. Prior
to incorporation within a paste, an addictive substance may be in any
suitable form known in the art, liquid, semi-liquid or solid, for example,
without limitation, powder, granules, spheroids, pellets, microspheres,
nanospheres, microcapsules, or crystals, and may be homogenously or
non-homogenously dispersed in the paste.
-9h-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
The novel composition of the present invention can be used in any
delivery device such as, and without being limited thereto, a sustained
release, pulsed release, delayed release and/or controlled release device that
controls the release of one or more active pharmaceutical ingredients. The
device can be a solid unit dosage form. The device can comprise a paste that
comprises, for example, one or more granules, one or more crystals, one or
more pellets and/or one or more spheroids. In a specific embodiment, the
device is a stable single homogeneous unit controlled release device which
controls the release rate, without significant variability, and with a
reproducible
controlled release rate.
The composition may be administered in any suitable manner using
any suitable formulation and/or dispensing device. For example and without
being limited thereto, the composition can be in the form of a suitable device
for in vivo oral, vaginal, anal, ocular, subcutaneous, intramuscular
administration or for implantation. The composition may also be used for in
vitro or ex vivo delivery of an addictive substance. It may be targeted at
specific sites in the gastrointestinal tract or to specific organs. It may be
applied buccally and transdermally in a pouch or patch. It is evident that the
physical state of the formulation and the particular method of application may
vary accordingly.
Paste compositions may be useful in formulation of addictive
substances to reduce the abuse potential of the addictive substance, for
example via alcohol extraction. However, it will be understood that the
utility of
paste compositions may not be limited to addictive substances, and may also
be useful in formulation of any active ingredient or substance.
The term "active ingredient" or "active substance" means any
compound which has biological, chemical, or physiological utility including,
without limitation, active pharmaceutical ingredient, drug, naturally
occurring
compound, nucleic acid compound, peptide compound, nutraceutical,
agricultural or nutritional ingredient or synthetic drug.
The term "addictive substance" means any compound upon which a
user may develop a psychic or physical dependence, including, without
-10-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
limitation, active pharmaceutical ingredient, drug, naturally occurring
compound, or synthetic drug.
Many interchangeable terms are commonly used to describe the
psychic or physical dependence of people upon compounds. The term
addiction is most commonly used when talking about the strong analgesics or
opiod agonist or abuse-able substances. The strong analgesics or opiod
agonist or abuse-able substances, in contrast to the weaker agents such as
aspirin, acetaminophen, and the like, are employed in the relief of more
severe pain. They usually produce a euphoric effect when crushed and
swallowed, snorted and "shoot" parenterally. When taken as oral controlled
release composition there is usually no significant euphoria.
Addiction can develop to the barbiturates and strong analgesic agents
or opiod agonist or abuse-able substances, in the sense of the term
"addiction" as defined by the Committee on Problems of Drug Dependence of
The National Research Council, namely, a compulsion to take the drug and to
increase the dose, with the development of psychic and sometimes physical
dependence on the effects of the drug, so that the development of means to
continue the administration of the drug becomes an important motive in the
addict's existence.
Addiction to narcotics or narcotic-like strong analgesics often occurs by
the legitimate chronic oral or parenteral administration of these agents in
the
alleviation of deep pain. More commonly, however, addiction to these agents
occurs when the psychologically unbalanced or thrill-seeking individual
looking for an escape from the realities of life finds his escape in the
euphoria
produced by the oral or parenteral administration of strong analgesics or
opiod agonist or abuse-able substances. Euphoria is generally defined as a
feeling of well-being. Euphoria can be produced in many ways, e.g., an
exhilarating experience, alcohol, stimulants, depressants, narcotics, etc. For
the purpose of this disclosure, "euphoria" is defined as an abnormal state of
well-being produced by the parenteral administration of strong analgesics.
Addictive substance encompasses the terms "abuse-able substances",
"euphoric analgesics" and "strong analgesics," often called narcotic or
-11-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
narcotic-like analgesics or opiod agonist, including, for example, those
chemical agents which upon oral or parenteral administration are capable of
maintaining or partially maintaining a known addict addicted to heroin or the
like without substantial withdrawal symptoms. For the purpose of this
disclosure, a "strong analgesic" can also be described as any analgesic agent
whose analgesic, euphoric or dependence producing actions are negated by
the parenteral administration of an opiod antagonist.
Examples of some of the opiod agonists or narcotic analgesics
contemplated for use in this invention include alfentanil, allylprodine,
alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine,
butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine,
diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol,
dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone,
eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine,
etonitazene, etorphine, dihydroetorphine, fentanyl hydrocodone,
hydromorphone, hydroxypethidine, isomethadone, ketobemidone,
levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol,
metazocine, methadone, metopon, morphine, myrophine, narceine,
nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene,
normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum,
pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine,
piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene,
sufentanil, tramadol,tilidine, alphaprodine, dextroporpoxyphene, propiram,
profadol, phenampromide, thiambutene, pholcodeine , 3-trans-dimethylamino-
4-phenyl-4-trans-carbethoxy-delta-cyclohexene, 3-d imethylamino-0-(4-
methoxyphenylcarbamoyl)-propiophenone oxime, (-)beta-2'-hydroxy-2,9-
dirnethyl-5-phenyl-6,7- benzomorphan, (-)2'-hydroxy-2-(3-methyl-2-butenyl)-9-
methyl-5-phenyl-6,7-benzomorphan, pirinitramide, (-)alpha-5,9-diethyl-2'-
hydroxy-2-methyl-6,7-benzomorphan, ethyl- 1-(2-d imethylaminoethyl)-4,5,6,7-
tetra hydro-3-methyl-4-oxo-6-phenylindole-2-carboxylate, 1-Benzoylmethyl-
2,3-dimethyl-3-(m-hydroxyphenyl)-piperidine, N-allyl-7alpha-(l-(R)-hydroxy-1-
methylbutyl)-6,14-endo-ethanotetrahydron ororipavine, (-)2'-hydroxy-2-methyl-
-12-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
6,7-benzomorphan, noracylmethadol, phenoperidine, alpha-dl-methadol, beta-
dl-methadol, alpha-l-methadol, beta-dl-acetylmethadol, alpha-1-
acetylmethadol and beta-l- acetylmethadol and pharmaceutically acceptable
salts thereof, stereoisomers thereof, ethers thereof, esters thereof, and
mixtures thereof.
Addictive substances also include drugs most commonly employed for
illicit purposes (to bring about a "high", euphoria, excitement, stupor, sleep
deprivation etc.,) such as the barbiturates, lysergic acid diethylamide (LSD),
mescaline, marijuana (tetrahydrocannabinol), heroin, and the like, the central
nervous system stimulants (the amphetamines and the like) sedative,
hypnotics and some of the major and minor tranquilizers (the promazines,
meprobamate, the diazepines, and the like)
Many addictive substances are commonly used in medicine for the
legitimate treatment of various conditions and therefore have a limited
availability in our society. While these agents are a necessary part of modern
medicine, it would be highly desirable (1) to produce new drugs that have
reduced drug abuse potential or (2) to "denature" the old agents to prevent
their illicit use. The pharmaceutical industry has been striving to achieve
the
first goal for many years but most regrettably has only achieved very
moderate success. If one focuses on the strong analgesics, it becomes
apparent that much effort and money has been expended to produce
chemicals possessing good analgesic activity but little or no addictive
liability.
While good progress has been made as evidenced, for example, by the
development of propoxyphene as a replacement for codeine and pentazocine
as a replacement for morphine or meperidine, these compounds are still
reported in the medical literature to be addictive and/or euphoric and
subjected to abuse by crushing and dissolving and heating/evaporation of the
drug composition to enable immediate access to the drug by swallowing,
inhalation, snorting, "shooting" or parenteral administration. Furthermore,
some of these agents have undesirable side effects, i.e., bad hallucinations,
etc.
-13-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
The compositions or devices of the present invention can also contain
other active ingredients. These include, amongst others and for example,
opiod antagonists (such as naloxone), aspirin, phenacetin, caffeine,
acetaminophen, antihistamines, homatropine methylbromide,
phenyltoloxamine citrate, barbiturates, or the like, or multiple combinations
thereof. Also included within the scope of the present invention are those
compositions comprising narcotic analgesics in combination with non narcotic
analgesics, antitussive preparations which contain narcotic or narcotic-like
cough suppressants such as codeine, dihyrocodeinone, pholcodeine, and the
like. Other products comprising a narcotic or narcotic-like composition for
use
as an antispasmotic in the gastro-intestinal tract, such as Camphorated
Opium Tincture, U.S.P., Opium Tincture, U.S.P., Opium extract, N.F., and the
like can be an integral part of certain examples of the present invention.
The term "paste" means a pharmaceutical form of thick or stiff
consistency. A paste may also comprise solids of less than 1000 microns
dipersed therein. A paste can also be described as a liquid or semi-solid
matrix or magma or paste which is non-newtonian, thixotropic or
pseudoplastic. A paste typically comprises an addictive substance. However,
a paste may comprise other active ingredients with or without the presence of
an addictive substance. Furthermore, a singular paste composition may be
used or combinations of two or more paste compositions having different
release profiles and/or comprising different active substances may be used.
The release profiles provided by the paste compositions of the present
invention may be advantageously used in the formulation of any active
ingredient.
Two or more populations of pastes with different release properties in a
singular or multiple dosage unit(s) may be used for delivery of the active
substances. One or more active substances can be delivered similarly, by use
of multiple paste populations. For example, formulating two active substances
in two paste compositions, respectively may be particularly useful if the
substances are incompatible or are to act seperately or at different onset of
-14-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
action. The different population of paste can be encapsulated or delivered in
any other suitable holding or dispensing device.
A paste may comprise one or more controlled release agent, and/or
one or more clays such as bentonite and/or one or more fillers in a
pharmaceutically suitable vehicle, and optionally materials selected from
disintegrants, humectants, surfactants and stabilizers. In certain examples, a
paste may comprise one or more controlled release agent, and/or one or
more clays such as bentonite and/or one or more fillers in a non-aqueous
vehicle, and optionally materials selected from disintegrants, humectants,
surfactants and stabilizers. In certain examples, a paste may comprise one or
more controlled release agent, and/or one or more clays such as bentonite
and/or one or more fillers in an aqueous vehicle, optionally comprising an
emulsifier for mixing with oily, fatty or waxy substances, and optionally
materials selected from disintegrants, humectants, surfactants and
stabilizers.
A paste composition may be formulated such that physicochemical
properties of the paste reduces or prevents dose dumping of active
substances. For example, a paste composition may be formulated such that
physicochemical properties of the paste reduces or prevents dose dumping of
addictive substances in the presence of alcohol, and discourages drug abuse
by mode of crushing, milling or grinding the dosage form to powder or heating
the dosage form to vapour and snorting or inhalation by the nasal route or
dissolving to abuse via the parenteral route.
The term "polymeric coating" or "polymeric coat" means any coating
which is formed by polymerization of one or more monomers to form linear or
branched or cross-linked macromolecules. The coating may be variously
characterized as a coating, layer, membrane, shell, capsule, or the like, and
substantially surrounds or envelope a core particle. Where a device of the
present invention comprises more than one polymeric coat, a first polymeric
coat substantially surrounds or envelopes a core particle, a second polymeric
coat substantially surrounds or envelopes the first polymeric coat, and so
forth. Polymeric coats may take the form and composition of any known
-15-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
compatible controlled-release coat, for example a pH sensitive coat, a water
repellant coat, or an aqueous solvent based coat, or a water soluble coat.
In certain examples, a polymeric coat may be prepared from a
homogenous mixture comprising a water soluble gel forming polymer and a
water insoluble organosoluble polymer in an organosolvent. While such a
preparation may be substantially non-aqueous, small amounts of water may
be used or tolerated, for example, less than about 20% (v/v), less than about
10% (v/v), less than about 5% (v/v) or less than about 2% (v/v) of the
polymeric coating composition before application to or incorporation into the
controlled-release delivery device.
The terms "sustained release", "pulsed release", "delayed release" and
"controlled release" are used interchangeably in this application and are
defined for purposes of the present invention as the release of an active
ingredient from a delivery device at such a rate that when a dose of the
active
ingredient is administered in the sustained release, pulsed release, delayed
release or controlled-release device, concentrations (levels) of the active
ingredient are maintained within a desired range but below toxic levels over a
selected period of time. In the case of in vivo administration, concentrations
(levels) of the active ingredient could be measured in blood or plasma, for
example. When administered in vivo the sustained release, pulsed release,
delayed release or controlled-release device of the present invention allows
for useful plasma concentration of an active ingredient to be maintained for
longer than in the case of immediate-release forms.
The controlled release profile may be modified on the basis of many
factors pertaining to the polymeric coats, for example, without limitation,
through the types of polymers used, the order in which they are deposited, the
ratios of the polymers in the mix and the nature of their interaction. The
controlled-release profile can also be modified by a variety of factors
relating
to the delivery device and the route of administration as outlined for
example,
in US Application No. 20070003619, published January 4, 2007. For example,
the sustained-release period will vary depending upon the solubility of the
active ingredient, the rate of clearance of the active ingredient from the
-16-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
intended site of administration, the size of the core particle, the amount of
the
active ingredient initially present in the core particle, the presence of
other
compounds within the core particle that affect the rate of release of the
active
ingredient, the permeability of the polymeric coating(s) to the active
pharmaceutical ingredient, and the rate of degradation of the polymeric
coating(s), as well as other factors.
Release control may be effected or optimized through the types of
polymers used, the order in which they are deposited, the number of
polymeric coats, the width of polymeric coats, the ratios of the polymers in
the
mix and the nature of their interaction.
It is commonly known to the narcotic enforcement agencies and others
in the medical trades that a substantial amount of the strong analgesics
destined for legitimate medicinal use are diverted to illicit use through
dishonest or careless handling. In many instances, these drugs are obtained
by the addict or potential addict by theft or casual prescribing practice by
the
physician.
It is known from experience that the true narcotic addict must feed his
habit by the crushing and/or dissolving and heating and/or evaporation of the
drug composition to enable immediate access to the drug by swallowing,
inhalation, snorting, "shooting" or parenteral route (mainlining) to obtain
the
maximum euphoric effect. The potential addict or thrill-seeker will also
experiment in the same manner. Unfortunately, a substantial amount of the
legitimate strong analgesics formulated in oral dosage form are diverted to
illicit parenteral use. Since the oral dosage forms of these drugs diverted
from
legitimate channels must be easily crushed, dissolved and heated
/evaporated in order to get a form in which it can be administered to produce
the desired euphoria, it follows that if these oral dosage forms are in some
way rendered difficult or impossible to crush, dissolve, heat/evaporate or
extract and made unpleasant for abuse via swallowing, snorting, inhalation
and "shooting" or parenteral use the addict or potential addict will be cut
off
from this particular supply of euphoric drugs. Obviously, oral activity must
be
retained if a useful medicament is to be provided.
-17-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Incorporating a pharmaceutical drug, that is an addictive substance, in
a paste composition may be useful for (1) reducing at least one mode of
abuse, for example, the illicit use by snorting/inhalation, parenteral
administration, or crushing and oral ingestion of dosage forms intended for
oral administration; (2) reducing dose dumping, for example in the presence
of alcohol; or (3) timed or extended release compositions and/or devices
which despite its pseudoplastic or thixotropic nature maintains its integrity
sufficiently to perform its controlled release functions during transit in the
GIT.
Paste compositions and comprise an addictive substance materials
selected from oily, waxy or fatty substances, clays or controlled release
agents can discourage abuse and make it harder to abuse by mode of
crushing, dissolving, heating to cause evaporation and snorting, "shooting" or
inhalation.
Paste compositions may optionally comprise a pharmaceutically
acceptable nasal irritant. A nasal irritant can produce nasal irritation and
annoyance feeling when the composition is brought in contact with the nasal
membrane. The irritant agent is not in amounts sufficient to precipitate
allergic
type reactions or immune response upon snorting. U.S. Pat. No. 7,157,103
(Sackler) issued Jan. 2, 2007, suggests the use of various irritants in
preparing pharmaceutical formulations including, for example, capsaicin, a
capsaicin analog with similar type properties as capsaicin, and the like. Some
capsaicin analogues or derivatives include for example, resiniferatoxin,
tinyatoxin, heptanoylisobutylamide, heptanoyl guaiacylamide, other
isobutylamides or guaiacylamides, dihydrocapsaicin, homovanillyl octylester,
nonanoyl vanillylainide, or other compounds of the class known as vanilloids.
Resiniferatoxin is described, for example, in U.S. Pat. No. 5,290,816
(Blumberg), issued Mar. 1, 1994. U.S. Pat. No. 4,812,446 (Brand), issued
Mar. 14, 1989, describes capsaicin analogs and methods for their preparation.
With the inclusion of an irritant (e.g., capsaicin) in a dosage form, when
the dosage form is tampered with, the capsaicin imparts a burning or
discomforting quality to the abuser to preferably discourage the inhalation,
injection, or oral administration of the tampered dosage form, and preferably
-18-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
to prevent the abuse of the dosage form. Suitable capsaicin compositions
include capsaicin (trans 8-methyl-N-vanillyl-6-noneamide) or analogues
thereof in a concentration between about 0.00125% and 50% by weight,
preferably between about 1 and about 7.5% by weight, and most preferably,
between about 1 and about 5% by weight of the dosage form.
Paste compositions are formulated such that an addictive substance
comprised therein is not easily soluble and immediately available upon
crushing and attempt at dissolving it for intravenous injection or to get
access
to the total drug immediately upon oral ingestion of the crushed dosage form
is not met with easy success.
A paste composition makes it harder for dose dumping of an addictive
substance in the presence of alcohol or during co-ingestion of alcohol. For
example, Figure 1 shows that a controlled release profile a paste composition
comprising oxycodone is maintained in varying concentrations of ethanol.
A paste composition will typically comprise a controlled release agent
or an oily, fatty or waxy substance, or a clay. When present in a paste
composition the concentration of a controlled release agent may be from
about 2% to about 90%. When present in a paste composition the
concentration of an oily substance may be from about 3% to about 99%.
When present in a paste composition the concentration of a fatty substance
may be from about 0.5 % to about 70%. When present in a paste composition
the concentration of a waxy substance may be from about 0.5 % to about
70%. When present in a paste composition the concentration of a clay may be
from about 0.1 % to about 95%.
Examples of clays suitable for use in a paste composition are
bentonite, veegum and other clay minerals such as phyllosilicates (Smectite,
illite, sepiolite, palygorskite, muscovite, allevardite, amesite, hectorite,
fluorohectorite, saponite, beidellite, talc, nontronite, stevensite, mica,
vermiculite, fluorovermiculite, halloysite and fluorine-containing synthetic
types of mica, phyllosilicates, beidellite; volkonskoite; hectorite;
sauconite;
sobockite; svinfordite; and the like. Other useful materials include micaceous
minerals, such as mixed illite/smectite minerals, such as rectorite,
tarosovite,
-19-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
ledikite and admixtures of illites with the clay minerals named above. A
swelling bentonite is preferred.
U.S. Pat. No. 4,517,112 teaches Modified organophilic clay complexes,
their preparation and non-aqueous systems containing them and more
especially, organophilic organic-clay complexes which are dispersible in
organic liquids to form a gel therein, which comprises the reaction product of
(a) a smectite-type clay having a cation exchange capacity of at least 75
milliequivalents per 100 grams of said clay; (b) a primary anion selected from
the group consisting of anions derived from organic sulfonic acids,
alkylsulfates and mixtures thereof containing at least one lineal or branched
alkyl group having greater than 9 carbon atoms, aromatic sulfonic acids and
mixtures thereof; (c) a secondary anion different from said primary anion and
selected from the group consisting of anions derived from organic acids
having a pKa of less than about 11.0 and mixtures thereof; and (d) an organic
cation is an amount sufficient to satisfy the cation in exchange capacity of
said
clay and the cationic activity of the primary and secondary anions wherein the
resulting organic cation-organic anion complexes are intercalated with the
smectite-type clay and wherein the combination of said primary and
secondary anion synergistically increases the ease of dispersion of said
organophilic clay gellant in an organic liquid. This invention relates to
compositions gels which may be useful as lubricating greases, oil base muds,
oil base packer fluids, paint-varnish-lacquer removers, paints, foundry
molding
sand binders, adhesives and sealants, inks, polyester laminating resins,
polyester gel coats, and the like.
U.S. Pat. No. 4,676,929 describes useful gels generated from
expandable, hydrated sheet silicates, also known as lattice layered silicates,
or phyllosilicates. It is also concerned with articles of manufacture produced
by further treatment of such gels, and with methods of generating and treating
the gels. The silicate minerals of interest include vermiculite, beidellite,
nontronite, volchonskoite, saponite, stevensite, sauconite, pimelite,
bentonite,
montmorillonite, hectorite, the smectites, attapulgite, sepiolite, phlogopite
and
-20-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
biopyrobole; i.e., in essence the entire genus of hydrated or hydratable
phyllosilicates whether of natural or synthetic origin.
When present in a paste composition the concentration of a clay may
be from about 0.1 % to about 95%. In certain examples, the amount of clay
may be from about 0.5% to about 20% (w/w) based on the total weight of the
paste composition. In other examples, the amount of clay may be from about
0.8% to about 20% (w/w) based on the total weight of the paste composition.
In still other examples, the amount of clay may be from about 1 % to about
20% (w/w) based on the total weight of the paste composition.
Oily, fatty or waxy components may also be used in a paste
composition and include any pharmaceutically acceptable oily, fatty or waxy
substance that is insoluble or substantially insoluble in ethanol or water.
These include oils and fats, waxes, hydrocarbons, higher fatty acids, higher
alcohols, esters, metal salts of higher fatty acids, and the like. Specific
examples of oils and fats include plant oils, e.g. cacao butter, palm oil,
Japan
wax (wood wax), coconut oil, corn oil, etc.; animal oils, e.g. beef tallow,
lard,
horse fat, mutton tallow, etc.; hydrogenated oils of animal origin, e.g.
hydrogenated fish oil, hydrogenated whale oil, hydrogenated beef tallow, etc.;
hydrogenated oils of plant origin, e.g. hydrogenated corn oil, hydrogenated
rape seed oil, hydrogenated castor oil, hydrogenated coconut oil,
hydrogenated soybean oil, etc.; and the like. Of these hydrogenated oils are
preferred as an oil component of the present invention. Specific examples of
waxes include plant waxes, e.g. carnauba wax, candelilla wax, bayberry wax,
auricurry wax, espalt wax, etc.; animal waxes, e.g. bees wax, breached bees
wax, insect wax, spermaceti, shellac, lanolin, etc.; and the like. Of these
preferred are carnauba wax, white beeswax and yellow beeswax. Paraffin,
petrolatum, microcrystalline wax, and the like, are given as specific examples
of hydrocarbons, with preferable hydrocarbons being paraffin and
microcrystalline wax. Given as examples of higher fatty acids are caprilic
acid,
undecanoic acid, lauric acid, tridecanic acid, myristic acid, pentadecanoic
acid, palmitic acid, malgaric acid, stearic acid, nonadecanic acid, arachic
acid,
heneicosanic acid, behenic acid, tricosanic acid, lignoceric acid,
pentacosanic
-21 -
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
acid, cerotic acid, heptacosanic acid, montanic acid, nonacosanic acid,
melissic acid, hentriacontanic acid, dotriacontanic acid, and the like. Of
these,
preferable are myristic acid, palmitic acid, stearic acid, and behenic acid.
Specific examples of higher alcohols are lauryl alcohol, tridecyl alcohol,
myristyl alcohol, pentadecyl alcohol, cetyl alcohol, heptadecyl alcohol,
stearyl
alcohol, nonadecyl alcohol, arachyl alcohol, behenyl alcohol, carnaubic
alcohol, corianyl alcohol, ceryl alcohol, and myricyl alcohol. Particularly
preferable alcohols are cetyl alcohol, stearyl alcohol, and the like. Specific
examples of esters are fatty acid esters, e.g. myristyl palmitate, stearyl
stearate, myristyl myristate, behenyl behenate, ceryl lignocerate, lacceryl
cerotate, lacceryl laccerate, etc.; glycerine fatty acid esters, e.g. lauric
monoglyceride, myristic monoglyceride, stearic monoglyceride, behenic
monoglyceride, oleic monoglyceride, oleic stearic diglyceride, lauric
diglyceride, myristic diglyceride, stearic diglyceride, lauric triglyceride,
myristic
triglyceride, stearic triglyceride, acetylstearic glyceride, hydoxystearic
triglyceride, etc.; and the like. Specific examples of metal salts of higher
fatty
acid are calcium stearate, magnesium stearate, aluminum stearate, zinc
stearate, zinc palmitate, zinc myristate, magnesium myristate, and the like.
In certain examples, the oils used in the invention may be one or more
selected from Almond Oil, Apricot Kernel Oil, Avocado Oil, Black Currant Oil,
14% GLA, Borage Oil, 20% GLA, Canola Oil, Carrot Oil, Castor Oil, Clove
Leaf Oil, Coconut Oil, Corn Oil, Cottonseed Oil, Evening Primrose Oil, 9%
GLA, Flaxseed Oil, 55% ALA, Grapeseed Oil, Hazelnut Oil, Hemp Oil, ALA /
GLA, Hydrogenated Oils, Jojoba Oil, Golden Jojoba Oil, Water-white Kukui
Nut Oil, Macadamia Nut Oil, Oat Oil, Olive Oil, Extra Virgin Olive Oil
Pomace/"B" grade, Olive Oil, Pure/NF, Palm Oil, Parsley Seed Oil, Peach
Kernel Oil, Peanut Oil, Pecan Oil, Pistachio Oil, Pumpkinseed Oil, Rice Bran
Oil, Rose Hip Seed Oil, Rosemary Oil, Safflower Oil, Linoleic' Safflower Oil,
High-Oleic, Sesame Oil NF, Sesame Oil Toasted, Soybean Oil, Sunflower Oil,
Salad Sunflower Oil High-Oleic, Tea Tree Oil, Vegetable, Glycerine, USP,
Walnut Oil, Wheat Germ Oil, Cold-pressed and mineral oil or other similar
oils.
-22-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Controlled release agents that may be used in the composition of this
invention include naturally occurring or synthetic, anionic or nonionic,
hydrophobic, hydrophilic rubbers, polymers, starch derivatives, cellulose
derivatives, polysaccharides, carbomer, reseins, acrylics, proteins, vinyl-
pyrrolidone-vinyl-acetate-copolymers, galactomannan and galactomannan
derivatives, carrageenans and the like. Specific examples are acacia,
tragacanth, Xanthan gum, locust bean gum, guar-gum, karaya gum, pectin,
arginic acid, polyethylene oxide, polyethylene glycol, propylene glycol
arginate, hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl
cellulose, hydroxyethyl cellulose, carboxymethylcelIulose sodium,
polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, alpha starch,
sodium carboxymethyl starch, albumin, dextrin, dextran sulfate, agar, gelatin,
casein, sodium casein, pullulan, polyvinyl alcohol, deacetylated chitosan,
polyethyoxazoline, poloxamers, ethylcellulose, chitin, chitosan, cellulose
esters, aminoalkyl methacrylate polymer, anionic polymers of methacrylic acid
and methacrylates, copolymers of acrylate and methacrylates with quaternary
ammonium groups, ethylacrylate methylmethacrylate copolymers with a
neutral ester group, polymethacrylates, surfactants, aliphatic polyesters,
zein,
polyvinyl acetate, polyvinyl chloride, and the like.
A pharmaceutically acceptable acrylic polymer may also be used in
certain examples. Specific examples include, but are not limited to, acrylic
acid and methacrylic acid copolymers, methyl methacrylate copolymers,
ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate
copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid
alkylamide copolyer, poly(methyl methacrylate), poly(methyl methacrylate)
copolymer, polyacrylamide, aminoalkyl methacrylate copolymer,
poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.
Additionally, the acrylic polymers may be cationic, anionic, or non-ionic
polymers and may be acrylates, methacrylates, formed of methacrylic acid or
methacrylic acid esters. The polymers may also be pH independent or pH
dependent.
-23-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
When present in a paste composition the concentration of a controlled
release agent may be from about 2% to about 90%. In certain examples, in
order to achieve the desired controlled release effect, the lower limit of the
controlled release agent may be greater than 2%, for example, at least about
5%, 10%, 15%, or 20% (w/w) based on the total weight of the paste
composition with the upper limit typically being less than 60% (w/w).
The controlled release profile of a paste composition may be modified
on the basis of many factors pertaining to the controlled release agent, for
example, without limitation, through the types of agents used, the order in
which they are deposited, the ratios of the agents in the mix and the nature
of
their interaction.
Further examples of additives that may be used in the composition of
the invention include, but are not limited to, ethyl lactate, phthalates such
as
dimethyl phthalate (DMP), diethyl phthalate (DEP), dibutyl phthalate (DBP),
dioctyl phthalate, glycol ethers such as ethylene glycol diethyl ether,
propylene glycol monomethyl ether, PPG-2 myristyl ether propionate,
ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, propylene
glycol monotertiary butyl ether, dipropylene glycol monomethyl ether, N-
methyl-2-pyrrol id one, 2 pyrrolidone, isopropyl myristate, isopropyl
palmitate,
octyl palmitate, dimethylacetamide, propylene glycol, propylene glycol
monocaprylate, propylene glycol caprylate/caprate, propylene glycol
monolaurate, glycofurol, linoleic acid, linoeoyl macrogol-6 glycerides, oleic
acid, oleic acid esters such as glyceryl dioleate, ethyl oleate, benzoic acid,
oleoyl macrogol-6 glycerides, esters such as ethylbenzoate, benzylbenzoate,
sucrose esters, sucrose acetate isobutyrate, esters of lactic acid, esters of
oleic acid, sebacates such as dimethyl sebacate, diethyl sebacate, dibutyl
sebacate, dipropylene glycol methyl ether acetate (DPM acetate), propylene
carbonate, propylene glycol laurate, propylene glycol caprylate/caprate,
gamma butyrolactone, medium chain fatty acid triglycerides, glycerol and
PEG esters of acids and fatty acids, PEG-6 glycerol mono oleate, PEG-6
glycerol linoleate, PEG-8 glycerol linoleate, caprylic acid esters such as
caprylocapryl macrogol-8 glycerides, PEG-4 glyceryl ca prylate/ca prate, PEG-
-24-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
8 glyceryl caprylate/caprate, polyglyceryl-3-oleate, polyglyceryl-6-'dioleate,
polyglyceryl-3-isostearate, polyglyceryl polyoleate, decaglyceryl tetraoleate
and glyceryl triacetate, glyceryl monooleate, glyceryl monolinoleate,
dimethylformamide, dimethylsulfoxide, tetrahydrofuran, caprolactam,
decylmethylsulfoxide, and, 1-dodecylazacycloheptan-2-one. The invention
may contain surface active agents with varying hydrophilic lipophilic balance
(HLB) values such as polyoxyethylene castor oil, polyoxyethylene
hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters,
polyoxyethylene alkyl esters, polyoxyethylene alkyl ethers, polyoxyethylene
glycerol esters, sorbitan fatty acid esters, and sodium lauryl sulphate.
Examples of antioxidants that may be used in this invention is selected
from ascorbic acid, fumaric acid, malic acid, alpha tocopherol, ascorbic acid
palmitate, butylated hydroxyanisole, propyl gallate, sodium ascobate, and
sodium metabisulfite or other suitable antioxidants and stabilizers.
Examples of plasticizers that may be used in this invention include
adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl
citrate, tri-n-butyl citrate, acetyl tri-n-butyl citrate, citric acid esters,
and those
described in the Encyclopedia of Polymer Science and Technology, Vol. 10
(1969), published by John Wiley & Sons. The preferred plasticizers are
triacetin, acetylated monoglyceride, acetyltributylcitrate,
acetyltriethylcitrate,
glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate,
dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate,
triethylcitrate, tributylcitrate, glyceroltributyrate, and the like. Depending
on the
particular plasticizer, amounts of from 0 to about 25%, and preferably about
0.1 % to about 20% of the plasticizer can be used. The addition of plasticizer
should be approached with caution so as not to compromise the integrity of
the gelatin capsule or cause leakage. In certain compositions it is better not
to
use plasticizers.
Examples of other additives that may be used as part of the
formulations of the invention include, but are not limited to carbohydrates,
sugars, sucrose, sorbitol, mannitol, zinc salts, tannic acid salts; salts of
acids
and bases such as sodium and potassium phosphates, sodium and
-25-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
potassium hydroxide, sodium and potassium carbonates and bicarbonates;
acids such as hydrochloric acid, sulfuric acid, nitric acid, and phosphoric
acid,
citric acid, tartaric acid, and benzoic acid.
Materials such as the alkali metal chlorides, ammonium chloride, and
chlorides of Ba, Mg, Ca, Cu, Fe and Al; alkali or alkaline earth solutions of
acetates, nitrates, phosphates, and hydroxides may be used in this invention.
Hygroscopic or aqueous materials may be used with caution. Limited
quantities have been incorporated in certain compositions. For example, a
paste composition may comprise an aqueous vehicle in combination with a
non-aqueous vehicle in the presence of an emulsifier.
The composition of the invention comprising one or more active
substances may be made by any method wherein the quantity or ratio and
type of clays, controlled release agents, oily, fatty or waxy substance and
optionally fillers is sufficient to form a paste, liquid or semi solid matrix,
magma of the entire composition. Preferably, the entire quantity of the
composition is dissolved, dispersed, emulsified or suspended in the oily,
fatty
or waxy substances. Typically, the clays, controlled release agent and oily,
fatty or waxy substances are combined, such as by blending or mixing under
high shear until the clays, controlled release agent is completely dissolved,
or
homogeneous paste is formed. The components may be added separately
one after the other. The active substance is added under high shear to form a
homogeneous non Newtonian, thixotropic or pseudoplastic paste or
liquid/semi solid matrix. The order of incorporation depends on the outcome to
be achieved. A cold process under room temperature conditions is preferred,
however solid substances may be heated to their liquid state prior to
incorporation.
Alternatively, the composition may be processed in a jacketed vessel
which allows precise control of the processing temperature. Other
pharmaceutically acceptable additives, such as those described above, may
be incorporated before, after, or during the addition of controlled release
agents or narcortic analgesics.
-26-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
The manufacture of the composition of this invention is relatively
simple. Formulation may be prepared at room temperature. Typically, no
heating of the ingredients are required. However, when materials that are
solid at room temperature are to be used, heating may be necessary.
Solvents having high volatile properties are typically not used. Examples of
such volatile solvents are: benzene, toluene, xylene, hexane, cyclohexanole,
cyclohexane, methylcyclohexanole, dioxane, ethylacetate, acetone,
amylacetate, propylacetate, methylethylketone, ethylcellosolve,
isopropylalcohol, methanol, ethylalcohol and isoamylalcohol.
In certain examples solid non-dissolved particles may be dispersed
within a paste. The solid particles will be of a size such that the paste
composition maintains its consistency/viscosity and homogeneity at room
temperature conditions and during storage. The solid particles may take any
convenient form, including, for example, granules, spheroids, pellets,
microspheres, nanospheres, microcapsules, or crystals and can be prepared
by wet or dry granulation, by extrusion spheronization, by powder or solution
layering, by microencapsulation techniques, by milling and compression
techniques or other suitable known techniques. In certain examples, different
populations of coated particles can be mixed together within a paste
composition.
In certain examples, the particle size of solid materials is less than
about 1000 microns and the composition maintains its consistency/viscosity
and homogeneity at room temperature conditions and during storage. In
certain other examples, the particle size of solid materials is less than
about
500, 200, 100, or 50 microns and the composition maintains its
consistency/viscosity and homogeneity at room temperature conditions and
during storage. In certain further, examples the solid particles are
sfficiently
small such that the paste composition is essentially a homogeneous non-
Newtonian, thixotropic or pseudoplastic paste.
A singular paste composition may be used or a combination of two or
more paste compositions may be used. In certain examples, a single paste
composition may comprise one or more active substances. In certain other
-27-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
examples, two or more paste compositions may have different release profiles
(for example, controlled release and immediate release) and may comprise
the same or different active substance(s). Multiple paste compositions may be
useful for delivery of one or more active substances. For example, multiple
paste compositions may be useful for delivery of two or more substances that
are incompatible or are to act seperately or at a different onset of action.
If
desired, multiple paste compositions may be encapsulated together or
delivered together in any other suitable dispensing device.
In certain examples, paste compositions are enveloped by capsules,
for example, soft of hard capsules. While both soft and hard capsules may be
used, hard capsules may be particularly useful. In certain examples, the
capsule is a hard gelatin capsule or is made of a metal or alloy of metals
from
the periodic table, cellulose ether, vegetable or animal origin.
Capsules are often made from gelatin. Gelatin capsules are
traditionally divided into two general groups; hard shell gelatin capsules and
soft gelatin capsules (softgels). In certain examples of hard shell gelatin
capsules, the capsule is typically in equilibrium with a relative humidity of
less
than 20%; is typically formulated with a low ratio of dry plasticizer to dry
gelatin (low amounts of plasticizer); and is typically made of two separately
formed, cooperating, telescoping shells. On the other hand, softgels are most
commonly in equilibrium with a relative humidity of between 20% and 30%,
are typically formulated with a high ratio of dry plasticizer to dry gelatin
(higher
amounts of plasticizer); and are typically formed in a unitary process such as
a rotary die encapsulation process.
Capsules from materials other than gelatin will also be known to the
skilled person. For example, US Patent Appln. Pub. No. 20060099246
(Tanner) published May 11, 2006 pertains to a non-gelatin soft capsule
system having a predominantly starch and gelling carrageenan based shell.
Carrageenan is a collective term for polysaccharides prepared by alkaline
extraction (and modification) from red seaweed (Rhodophycae), mostly of
genus Chondrus, Eucheuma, Gigartina and Iridaea. Different seaweeds
produce different carrageenans. Carrageenan consists of alternating 3-linked-
-28-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
beta-D-galactopyranose and 4-linked-alpha-D-galactopyranose units. Most, if
not all, of the galactose units are substituted with sulfate ester groups. As
another example, US Patent Appin. Pub. No. 20060004193 (Muller) published
January 5, 2006 relates to a tough-elastic material based on starch, which on
the one hand has high impact toughness at low humidities, and on the other
hand still has a high modulus of elasticity at high humidities and has a high
elongation capacity in a broad range of humidities and on account of its
property profile is suited to use as edible film and for the packaging of
active
ingredients, as well as high-quality substitution of gelatine in the area of
soft
and hard capsules. As another example, PCT publication WO 01/37817
describes a soft capsule based on thermoplastic starch (TPS) with high
softener content. As another example, US Patent Appln. Pub. No.
20050196436 (Chantranukul) published September 8, 2005, relates to a
method of producing a film forming blend of different acyl gellan gums with
starch having similar textural and functional properties compared to gelatin.
As another example, US Patent Appln. Pub. No. 20070077293 (Park)
published April 5, 2007 relates to a film-forming composition for hard
capsules, comprising 7-12% by weight of starch, 1-6% by weight of a
plasticizer, 0.7-3% by weight of a gelling agent, and 79-91.3% by weight of
water. As another example, US Patent Appln. Pub. No. 20060153909
(Motoune) published July 13, 2006, relates to hard capsules made of a base
material containing a cellulose derivative including, for example, one or more
of hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl cellulose,
hydroxyethyl cellulose, hydroxypropyl methylcellulose phthalate,
hydroxypropyl methylcellulose acetate succinate, carmelose,
carboxymethylethyl cellulose, cellulose acetate phthalate, and ethylcellulose.
Also, additives such as a gelling agent, a gelling aid, a colorant, a
plasticizer,
an emulsifier, a dispersant, and a preservative may be added to the capsule
base material. As yet another example, US Patent Appln. Pub. No.
20050186268 (Hoshi) published August 25, 2005, describes a hard capsule
made mainly of a polymer or copolymer obtained by polymerizing or
copolymerizing at least one polymerizable vinyl monomer in the presence of
-29-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
polyvinyl alcohol and/or a derivative thereof. Still many other examples
exist,
as will be recognized by the skilled person.
In certain examples, a controlled release composition may be filled into
a capsule or dispensing device alone and utilized, or it may be co-filled with
non controlled release composition containing opiod antagonist and/or
immediate release non narcotic analgesics or other pharmaceutically active
substances.
Paste compositions allow for a clean break during formation or dosing
("stringing") into gelatin capsule or device. With regard to two-piece
capsules,
the paste composition should be of sufficient viscosity to prevent possible
splashing of the bushings that may occur and which could contaminate the
area of overlap between the capsule body and cap and prevent a good seal
from being formed.
Capsules comprising paste compositions may be prepared by any
number of known suitable techniques. The fill material used in a capsule
generally contains a pharmaceutical dissolved or dispersed in a carrier that
is
compatible with the capsule wall.
In certain examples, a liquid or semi-solid matrix, magma or paste is
filled in a gelatin capsule for which dissolution using a USP dissolution
tester
is not significantly different by the rotation speed of the basket or paddle
in the
speed range from about 25 rpm to about 150 rpm, or at about 50 rpm and
about 100 rpm or at about 50 rpm and about 75 rpm or at about 100 rpm and
about 150 rpm. The rotation speed does not interact with or compromise the
integrity of the composition and release mechanism. Compositions that meet
these requirements perform consistently in the gastrointestinal tract without
fear of collapse or disintegration, They are typically not perturbed, crushed
or
damaged by gastrointestinal tract content, resident time or motility. These
types of composition may be prized for their reliability.
Compositions comprising addictive substances, clays, controlled
release agents or oily, waxy or fatty substances are formulated to be
compatible with the gelatin capsule shell and not compromise the integrity of
the capsule shell.
-30-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
A gelatin capsule may be coated on the internal and/or external surface
of the gelatin capsule in order to control the site and/or rate of delivery of
an
active substances or protect the composition from environmental factors such
as moisture or for aesthetic appeal.
A capsule or other particles may be coated with a polymeric coating.
Methods of polymeric coating are well known in the art. For example, a core
particle may be coated in a fluidized bed or pan, or by spraying or painting a
polymeric coat onto a core particle. Another known option is a fluid bed
bottom spray coater by having particles suspended in an air stream, and an
aqueous dispersion of a polymeric coating composition is sprayed on to the
particles. Various conventional coating apparatuses may be employed to
facilitate this including, for example, a centrifugal fluidized bed coating
apparatus, a pan coating apparatus, or a fluidized bed granulating coating
apparatus.
Water insoluble organosoluble polymers which are used in the present
invention may be any polymers which are insoluble in water, are capable of
being homogenously dissolved or dispersed in an organosolvent, and can
typically retard the release of active ingredients. By the term "water-
insoluble"
is intended not susceptible to being dissolved (in water). Specific examples
of
water insoluble organosoluble polymers are, cellulose ether, cellulose ester,
or cellulose ether-ester e.g., ethyl cellulose, acetyl cellulose, and
nitrocellulose. Other water insoluble organosoluble polymers that can be used
include acrylic and/or methacrylic ester polymers, polymers or copolymers of
acrylate or methacrylate polyvinyl esters, polyvinyl acetates, polyacrylic
acid
esters, and butadiene styrene copolymers., and the like. Preferred water
insoluble polymers are, ethylcellulose, cellulose acetate, polymethacrylates
and aminoalkyl methacrylate copolymer.
In further specific examples, the acrylic polymer, includes, but is not
limited to, acrylic acid and methacrylic acid copolymers, methyl methacrylate
copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl
methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid),
methacrylic
acid alkylamide copolyer, poly(methyl methacrylate), poly(methyl
-31-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate
copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate
copolymers. Additionally, the acrylic polymers may be cationic, anionic, or
non-ionic polymers and may be acrylates, methacrylates, formed of
methacrylic acid or methacrylic acid esters. The water insoluble polymers can
be used either singly or in combinations of two or more.
Water soluble gel forming polymers which may be used in the present
invention may be any polymers which are soluble in water, are capable of
being homogenously dissolved or dispersed in an organosolvent, and can
typically retard the release of active ingredients. Typically, the water
soluble
gel forming polymer is capable of hydrating quickly and forming strong,
viscous gels. By the term "water-soluble" is intended susceptible of being
dissolved (in water). Suitable water soluble gel forming polymers include
those which can form hydrocolloid or can form a strong, viscous gel through
which an active ingredient is released via diffusion or wicking. They include
naturally occurring or synthetic, anionic or nonionic, hydrophilic rubbers,
starch derivatives, cellulose derivatives, proteins, and the like. Specific
non-
limiting examples are gelatin, such as alginates, pectins, carrageenans, or
xanthan; cellulose derivatives, such as methyl cellulose,
hydroxypropylcelIulose, hydroxyethylcelIulose, hydroxypropyl methylcellulose,
or sodium carboxymethylcelIulose; starch and starch derivatives such as
alpha starch or sodium carboxymethyl starch; galactomannan and
galactomannan derivatives; polyvinylpyrrolidone, polyvinyl alcohol, vinyl-
pyrrolidone-vinyl-acetate-copolymers, acacia, tragacanth, xanthan gum, locust
bean gum, guar-gum, karaya gum, pectin, arginic acid, polyethylene oxide,
Carbomer, polyethylene glycols, polypropylene glycols, carboxyvinyl polymer,
sodium polyacrylate, albumin, dextrin, dextran sulfate, agar, gelatin, casein,
sodium casein, pullulan, deacetylated chitosan, polyethyoxazoline,
polyethylene oxide, poloxamers and the like. Of these, preferable are
hydroxyethyl cellulose, hydroxypropyl methylcellulose, methylcellulose,
hydroxypropyl cellulose, carbomer, polyethylene glycol, poloxamers, , starch
-32-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
derivatives and polyvinylpyrrolidone. Water soluble gel forming polymers can
be used either singly or in combinations of two or more.
Polymeric coats may also be comprised of: hydrophobic or water
repellant material such as oils, fats, waxes, higer alcohols;pH sensitive
polymers; enteric polymers; or any other polymer, component or material
known to be useful for preparing a controlled release coating.
The polymers used in the present invention may be pH insensitive or
pH sensitive.
For a delivery device designed to be orally administered to the
digestive tract, polymers that are known to be orally ingestible can be used
and include, for example, polyvinyl alcohol, hydroxypropyl methyl cellulose,
and other cellulose-based polymers. Other known polymers useful for enteral
delivery include polymer materials which preferentially dissolve or
disintegrate
at different points in the digestive tract. Such polymers include, for
example,
the known acrylic and/or methacrylic acid-based polymers which are soluble
in intestinal fluids, e.g. the EudragitTM series of commercially available
polymers. Examples of these include Eudragit ETM, such as Eudragit E 100TH
which preferentially dissolves in the more acid pH of the stomach, or enteric
polymers such as Eudragit LTM and/or Eudragit STM which preferentially
dissolve in the more alkaline pH of the intestine, or polymers which dissolve
slowly, e.g. a predetermined rate in the digestive tract, such as Eudragit
RLTM
e.g. Eudragit RL 100TM, and/or Eudragit RSTM e.g. Eudragit R100TM, and/or
blends of such EudragitTM polymers.
Hydrophobic or water repellant material that may be present in a coat
is chosen from oil and fats, waxes, higher fatty acids, fatty acid esters,
higher
alcohols, hydrocarbons, and metal salts of higher fatty acids. Specific
examples of oils and fats include plant oils, e.g. cacao butter, palm oil,
Japan
wax (wood wax), coconut oil, etc.; animal oils, e.g. beef tallow, lard, horse
fat,
mutton tallow, etc.; hydrogenated oils of animal origin, e.g. hydrogenated
fish
oil, hydrogenated whale oil, hydrogenated beef tallow, etc.; hydrogenated oils
of plant origin, e.g. hydrogenated rape seed oil, hydrogenated castor oil,
hydrogenated coconut oil, hydrogenated soybean oil, etc.; and the like. Of
-33-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
these hydrogenated oils are preferred as an oil component of the present
invention.
Specific examples of waxes include plant waxes, e.g. carnauba wax,
candelilla wax, bayberry wax, auricurry wax, espalt wax, etc.; animal waxes,
e.g. bees wax, breached bees wax, insect wax, spermaceti, shellac, lanolin,
etc; and the like. Of these preferred are carnauba wax, white beeswax and
yellow beeswax.
Paraffin, petrolatum, microcrystalline wax, and the like, are given as
specific examples of hydrocarbons, with preferable hydrocarbons being
paraffin and microcrystalline wax.
Given as examples of higher fatty acids are caprilic acid, undecanoic
acid, lauric acid, tridecanic acid, myristic acid, pentadecanoic acid,
palmitic
acid, malgaric acid, stearic acid, nonadecanic acid, arachic acid,
heneicosanic
acid, behenic acid, tricosanic acid, lignoceric acid, pentacosanic acid,
cerotic
acid, heptacosanic acid, montanic acid, nonacosanic acid, melissic acid,
hentriacontanic acid, dotriacontanic acid, and the like. Of these, preferable
are
myristic acid, palmitic acid, stearic acid, and behenic acid.
Specific examples of higher alcohols are lauryl alcohol, tridecyl alcohol,
myristyl alcohol, pentadecyl alcohol, cetyl alcohol, heptadecyl alcohol,
stearyl
alcohol, nonadecyl alcohol, arachyl alcohol, behenyl alcohol, carnaubic
alcohol, corianyl alcohol, ceryl alcohol, and myricyl alcohol. Particularly
preferable alcohols are cetyl alcohol, stearyl alcohol, and the like.
Specific examples of esters are fatty acid esters, e.g. myristyl
palmitate, stearyl stearate, myristyl myristate, behenyl behenate, ceryl
lignocerate, lacceryl cerotate, lacceryl laccerate, etc.; glycerine fatty acid
esters, e.g. lauric monoglyceride, myristic monoglyceride, stearic
monoglyceride, behenic monoglyceride, oleic monoglyceride, oleic stearic
diglyceride, lauric diglyceride, myristic diglyceride, stearic diglyceride,
lauric
triglyceride, myristic triglyceride, stearic triglyceride, acetyistearic
glyceride,
hydoxystearic triglyceride, etc.; and the like. Glycerine fatty acid esters
are
more preferable.
-34-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Specific examples of metal salts of higher fatty acid are calcium
stearate, magnesium stearate, aluminum stearate, zinc stearate, zinc
palmitate, zinc myristate, magnesium myristate, and the like, with preferable
higher fatty acid salts being calcium stearate and magnesium stearate.
An polymeric coating composition may also contain other additives
normally found in coatings used in the pharmaceutical art such as
plasticizers,
anti-tacking agents such as talc and coloring agents.
Examples of plasticizers include diethylphthalate, triethyl citrate, triethyl
acetyl citrate, triacetin, tributylcitrate, polyethylene glycol, glycerol,
vegetable
and mineral oils. When using capsules, the addition of plasticizer should be
approached with caution so as not to compromise the integrity of the gelatin
capsule or cause leakage. In certain compositions it is better not to use
plasticizers.
Coloring agents are added for elegance and aesthetics or to
differentiate products and may be chosen, for example, from metal oxide
pigments or aluminum lake dyes.
A coating composition may include an anti-tacking agent such as talc.
Other examples of suitable anti-tacking agent are calcium stearate, colloidal
silicon dioxide, glycerin, magnesium stearate, and aluminum stearate.
In a specific example, an polymeric coating is prepared by adding
polymers, plasticizer, and anti-tacking agent to an organosolvent and mixed
until homogenously dissolved or dispersed using a high shear mixer. The
coating may be applied to a core particle using standard coating methodology.
A paste composition of the present invention may be used for
treatment of a patient, for example, an animal and more particularly, a
mammal. By mammal, is meant any member of the class of mammalia that is
characterized by being a vertebrate having hair and mammary glands.
Examples include, without limitation, dog, cat, rabbit, horse, pig, goat, cow,
human being. The paste composition of the present invention may be
administered to any animal patient or mammalian patient that is in need of
treatment with a site specific, timed, pulsed, chronotherapeutic, extended, or
controlled release of an active ingredient. In one example, a delivery device
of
-35-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
the present invention is used for treating a horse. In another example, a
delivery device of the present invention is used for treating a human being.
A medical condition or dose dumping may be prevented or treated by
administering to a patient a paste composition comprising a therapeutically
effective amount of an addictive substance.
In certain examples of methods of preparing or using a paste
composition, the administration in man or animal may be internal, such as oral
or parenteral. Such internal parenteral administration includes but is not
limited to intravascular, intramuscular, subcutaneous, intradermal,
intrathecal,
and intracavitary routes of administration, as well as application to the
external surface of an internal bodily organ, such as during a surgical or
laparoscopic procedure. The administration may be topical, including
administration to the skin or to a mucosal surface, including the oral,
vaginal,
rectal surfaces, to the surface of the eye, to the nasal passages, or to the
ear
canal.
The composition may also be in the form of a solid. The means and
area of application will depend on the particular condition that is being
treated.
The composition may be dispensed using any suitable formulation and/or
dispensing device. For example, it may be taken orally, implanted,
intravenously or as a depot. It may be targeted at specific sites in the
gastrointestinal tract (GU) or to specific organs. As another example, the
composition may also be applied buccally and transdermally in a pouch or
patch.
The composition may be applied to bodies of water, such as rivers,
lakes, or oceans, to the atmosphere, or to land. It is evident that the
physical
state of the formulation and the particular method of application may vary
accordingly.
Solid particles may be prepared by conventional techniques. The
preferred technique is by dry or wet granulation of an addictive substance and
excipients such as solubulizing agents, emulsifying agents, suspending
agents, fillers, compression agents, stabilizers, pH altering agents, buffers,
lubricants, and glidants.
-36-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Fillers, such as lactose, and compression agents such as
microcrystalline cellulose, lubricants such as magnesium stearate and
glidants such silicone dioxide may, in certain examples, be included in the
core. The core onto which the coating is applied contains the active
component. The core may be a tablet, capsule, caplet, pellet, spherical or
irregular in shape.
In certain examples, swellable polymeric materials such as hydrogels
that swell and expand significantly are included in the core.
Excipients may be homogenously mixed with an active ingredient in a
core particle. Excipients may be selected from antiadherents, binders,
diluents, emulsifying agents, suspending agents, compression agents,
extrusion agents, pH altering agents, buffers, glidants, lubricants,
solubilizers,
wetting agents, surfactants, penetration enhancers, pigments, colorants,
flavoring agents, sweetners, antioxidants, acidulants, stabilizers,
antimicrobial
preservatives and binders.
Excipients are biologically inert ingredients which enhance the
therapeutic effect. The filler or diluent (eg lactose or sorbitol)is a bulking
agent, providing a quantity of material which can accurately be formed into a
tablet. The binders and adhesives(eg methyl cellulose or gelatin) hold the
ingredients together so that they form a tablet and hold together. Lubricants
(eg magnesium stearate or polyethylene glycol) are added to improve powder
flow so that the die fills accurately, they also reduce the friction between
the
tablet and the machine so that the process progresses smoothly and
uniformly.
Antiadherents are used to reduce the adhesion between the powder
(granules) and the punch faces and thus prevent tablet sticking to the
punches.
Binders hold the ingredients in a tablet together. Binders ensure that
tablets and granules can be formed with required mechanical strength.
Binders may be selected from starches, sugars, cellulose or modified
cellulose such as hydroxypropyl cellulose, lactose, or sugar alcohols like
xylitol, sorbitol or maltitol. Solution binders are dissolved in a solvent
(for
-37-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
example water or alcohol and used in wet granulation processes. Examples of
solution binders are gelatin, cellulose, cellulose derivatives, polyvinyl
pyrrolidone, starch, sucrose and polyethylene glycol. Dry binders are added to
a powder blend, either after a wet granulation step, or as part of a direct
powder compression. Examples of dry binders are cellulose, methyl cellulose,
polyvinyl pyrrolidone, polyethylene glycol. A commonly used binder or
compression agent is microcrystalline cellulose. Microcrystalline and
powdered cellulose products are sold under the tradenames Avicel.TM. PH
(FMC Corporation, Philadelphia, Pa.) and Solka Floc.TM. (Penwest Company,
Patterson N.Y.). Microcrystalline cellulose may be used in various techniques
such as direct compression, dry granulation, wet granulation, or extrusion-
spheronization.
Compression agents are materials that may be compacted.
Compression agents may be added to increase the overall hardness of a core
particle. Compression agents have inherently high compactibility due to
properties of plastic deformation and limited elastic recovery. Non-limiting
examples of materials that find use as compression agents are
microcrystalline cellulose, silicified microcrystalline cellulose (for example
ProsolvTM produced by JRS Pharma), oxidized polyethylene, calcium
hydrogen phosphate dehydrate, dextrate, or sugar.
Fillers or diluents are added for bulk to fill out the size of a tablet or
capsule, making it practical to produce and convenient for the consumer to
use. Fillers/diluents are typically inert, compatible with the other
components
of the formulation, non-hygroscopic, soluble, relatively cheap, compactible,
and preferably tasteless or pleasant tasting. Plant cellulose (pure plant
filler) is
a popular filler in tablets or hard gelatin capsules. Dibasic calcium
phosphate
is another popular tablet filler. A range of vegetable fats and oils can be
used
in soft gelatin capsules. Other examples of fillers include: lactose, sucrose,
glucose, mannitol, sorbitol, and, calcium carbonate. Fillers/diluents are
typically selected from microcrystalline cellulose, plant cellulose, calcium
phosphate, mannitol, sorbitol, xylitol, glucitol, ducitol, inositiol,
arabinitol;
arabitol, galactitol, iditol, allitol, fructose, sorbose, glucose, xylose,
trehalose,
-38-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
al lose, dextrose, altrose, gulose, idose, galactose, talose, ribose,
arabinose,
xylose, lyxose, sucrose, maltose, lactose, lactulose, fucose, rhamnose,
melezitose, maltotriose, and raffinose. Preferred sugars include mannitol,
lactose, sucrose, sorbitol, trehalose, glucose.
Glidants are used to improve the flowability of the powder or granules
or both. Some examples of glidant(s) are silicon dioxide, starch, calcium
silicate, Cabosil, Syloid, and silicon dioxide aerogels. Typically, silicon
dioxide
is used.
Lubricants prevent ingredients from clumping together and from
sticking to the tablet punches or capsule filling machine. Lubricants also
ensure that tablet formation and injection can occur with low friction between
the solid and die wall. Some examples of lubricant(s) are alkali stearates
such
as magnesium stearate, calcium stearate, zinc stearate, polyethylene glycol,
adipic acid, hydrogenated vegetable oils, sodium chloride, sterotex, glycerol
monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl
sulfate, magnesium lauryl sulfate, sodium stearyl fumarate, light mineral oil
and the like may be employed. Waxy fatty acid esters, such as glyceryl
behenate, sold as "Compritol" products, can be used. Other useful
commercial lubricants include "Stear-O-Wet" and "Myvatex TL". Common
minerals like talc or silica, and fats, e.g. vegetable stearin, glycerol
monostearate, magnesium stearate or stearic acid are typically used
lubricants.
Sorbents are used for moisture-proofing by limited fluid sorbing (taking
up of a liquid or a gas either by adsorption or by absorption) in a dry state.
Surfactants, wetting agents and solubilisers such as glycerol
monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan
esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as
cetomacrogol 1000), polyoxyethlylene castor oil derivatives, polyoxyethylene
sorbitan fatty acid esters (e.g., TWEENTM), polyoxyethylene stearates, sodium
dodecylsulfate, Tyloxapol (a nonionic liquid polymer of the alkyl aryl
polyether
alcohol type, also known as superinone or triton) is another useful
solubilisers.
Most of these solubilisers, wetting agents and surfactants are known
-39-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
pharmaceutical excipients and are described in detail in the Handbook of
Pharmaceutical Excipients, published jointly by the American Pharmaceutical
Association and The Pharmaceutical Society of Great Britain (The
Pharmaceutical Press, 1986).
Preferred wetting agents include tyloxapol, poloxamers such as
PLURONICTM F68, F127, and F108, which are block copolymers of ethylene
oxide and propylene oxide, and polyxamines such as TETRONICTM 908 (also
known as POLOXAMINETM 908), which is a tetrafunctional block copolymer
derived from sequential addition of propylene oxide and ethylene oxide to
ethylenediamine (available from BASF), dextran, lecithin, dialkylesters of
sodium sulfosuccinic acid such as AEROSOL TM OT, which is a dioctyl ester of
sodium sulfosuccinic acid (available from American Cyanimid), DUPONOLTM
P, which is a sodium lauryl sulfate (available from DuPont), TRITON TM X-200,
which is an alkyl aryl polyether sulfonate (available from Rohm and Haas),
TWEENTM 20 and TWEENTM 80, which are polyoxyethylene sorbitan fatty acid
esters (available from ICI Specialty Chemicals), Carbowax 3550 and 934,
which are polyethylene glycols (available from Union Carbide), Crodesta F-
110, which is a mixture of sucrose stearate and sucrose distearate, and
Crodesta SL-40 (both available from Croda Inc.), and SA90HCO, which is
Cg18H37-CH2 (CON(CH3)CH2(CHOH)4 CF20H)2.
Wetting agents which have been found to be particularly useful include
Tetronic 908, the Tweens, Pluronic F-68 and polyvinylpyrrolidone. Other
useful wetting agents include decanoyl-N-methylglucamide; n-decyl-.beta.-D-
glucopyranoside; n-decyl-. beta. -D-maItopyranoside; n-dodecyl-. beta.-D-
glucopyranoside; n-dodecyl.beta.-D-maltoside; heptanoyl-N-methylglucamide;
n-heptyl-.beta.-D-glucopyranoside; n-heptyl-.beta. -D-thiogIucoside; n-hexyl-
.beta.-D-glucopyranoside; nonanoyl-N-methylglucamide; n-octyl-.beta.-D-
glucopyranoside; octanoyl-N-methylglucamide; n-octyl-.beta.-D-
glucopyranoside; and octyl-.beta. -D-thiogIucopyranoside. Another preferred
wetting agent is p-isononylphenoxypoly(glycidol), also known as Olin-10G or
Surfactant 10-G (commercially available as 1 OG from Olin Chemicals). Two or
more wetting agents can be used in combination.
-40-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
The pharmaceutical composition or device may further include a
pegylated excipient. Such pegylated excipients include, but are not limited
to,
pegylated phospholipids, pegylated proteins, pegylated peptides, pegylated
sugars, pegylated polysaccharides, pegylated block-co-polymers with one of
the blocks being PEG, and pegylated hydrophobic compounds such as
pegylated cholesterol. Representative examples of pegylated phospholipids
include 1,2-diacyl 1-sn-glycero-3-phosphoethanolamine-N-[Poly(ethylene
glycol) 2000] ("PEG 2000 PE") and 1,2-diacyl-sn-glycero-3-
phosphoethanolamine-N-[- Poly(ethylene glycol) 5000]("PEG 5000 PE"),
where the acyl group is selected, for example, from dimyristoyl, dipalmitoyl,
distearoyl, diolcoyl, and 1-palmitoyl-2-oleoyl.
Additional excipients may be included in the composition of the present
invention. Further examples of excipients can include pigments, colorants,
flavoring agents, preservatives and sweetners. Flavors and colors are added
to improve the taste or appearance of a formulation. Some typical
preservatives used in pharmaceutical formulations are antioxidants such as
vitamin A, vitamin E, vitamin C, and selenium, amino acids such as cysteine
and methionine, citric acid and sodium citrate, or synthetic preservatives
such
as methyl paraben and propyl paraben. Sweeteners are added to make the
ingredients more palatable, especially in chewable tablets such as antacid or
liquids like cough syrup. Sugar may be used to disguise unpleasant tastes or
smells.
One skilled in the art can select appropriate excipients for use in the
composition of the present invention.
The paste composition may comprise an excipient that is a swellable
material such as a hydrogel in amounts that can swell and expand. Examples
of swellable materials include hydrophilic polymers that are lightly cross-
linked, such cross-links being formed by covalent or ionic bond, which
interact
with water and aqueous biological fluids and swell or expand to some
equilibrium state. Swellable materials such as hydrogels exhibit the ability
to
swell in water and retain a significant fraction of water within its
structure, and
when cross-linked they will not dissolve in the water. Swellable polymers can
-41 -
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
swell or expand to a very high degree, exhibiting a 2 to 50 fold volume
increase. Specific examples of hydrophilic polymeric materials include
poly(hydroxyalkyl methacrylate), poly(N-vinyl-2-pyrroIidone), anionic and
cationic hydrogels, polyelectrolyte complexes, poly(vinyl alcohol) having a
low
acetate residual and cross-linked with glyoxal, formaldehyde, or
glutaraldehyde, methyl cellulose cross-linked with dialdehyde, a mixture of
cross-linked agar and carboxymethyl cellulose, a water insoluble, water-
swellable copolymer produced by forming a dispersion of finely divided
copolymer of maleic anhydride with styrene, ethylene, propylene, butylene, or
isobutylene cross-linked with from 0.001 to about 0.5 moles of a
polyunsaturated cross-linking agent per mole of maleic anhydride in the
copolymer, water-swellable polymers of N-vinyl lactams, cross-linked
polyethylene oxides, and the like. Other examples of swellable materials
include hydrogels exhibiting a cross-linking of 0.05 to 60%, hydrophilic
hydrogels known as Carbopol.TM. acidic carboxy polymer, Cyanamer.TM.
polyacrylamides, cross-linked water-swellable indene-maleic anhydride
polymers, Good-rite.TM. polyacrylic acid, polyethyleneoxide, starch graft
copolymers, Aqua-Keeps.TM. acrylate polymer, diester cross-linked
polyglucan, and the like. Methods for testing swellable materials with regards
to polymer imbibition pressure and hydrogel-water interface interaction are
described in US Patent No. 4,327,725 issued May 4, 1982, titled "Osmotic
device with hydrogel driving member".
In a certain example, the device may be coated with a non-
disintegrating and non-semi-permeable coat. Materials useful for forming the
non-disintegrating non-semi-permeable coat are ethylcellulose,
polymethylmethacrylates, methacrylic acid copolymers and mixtures thereof.
In yet another embodiment, the device is coated with a non-
disintegrating semipermeable coat. Materials useful for forming the non-
disintegrating semipermeable coat are cellulose esters, cellulose diesters,
cellulose triesters, cellulose ethers, cellulose ester-ether, cellulose
acylate,
cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose
diacetate,
cellulose triacetate, cellulose acetate propionate, and cellulose acetate
-42-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
butyrate. Other suitable polymers are described in U.S. Pat. Nos. 3,845,770,
3,916,899, 4,008,719, 4,036,228 and 4,612,008. The most preferred non-
disintegrating semipermeable coating material is cellulose acetate comprising
an acetyl content of 39.3 to 40.3%, commercially available from Eastman Fine
Chemicals.
In an alternative embodiment, the non-disintegrating semipermeable or
non-disintegrating non-semi-permeable coat can be formed from the above-
described polymers and materials that will form pores or channels in the coat.
The pore forming agents or channeling agents dissolve on contact with fluid
and form passages through which fluid and active pharmaceutical
ingredient(s) can move through the coat. The pore forming agent or
channeling agent can be a water soluble material or an enteric material.
Some general examples of pore forming agents or channeling agents are
watersoluble materials such as cellulose ethers, polyethylene glycols or
microcrystalline cellulose. Some further examples of pore forming agents or
channeling agents are sodium chloride, potassium chloride, lactose, sucrose,
sorbitol, mannitol, polyethylene glycol (PEG), for example PEG 600, polyvinyl
pyrolidone, propylene glycol, hydroxypropyl cellulose, hydroxypropyl
methycellulose, hydroxypropyl methycellulose phthalate, cellulose acetate
phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures
thereof.
The active pharmaceutical ingredient(s) that are water soluble or that
are soluble under intestinal conditions may also be used to create pores in
the
coat.
The pore forming agent comprises approximately 0 to about 75% of the
total weight of the coating, most preferably about 0.5% to about 25% of the
total weight of the coating. The pore forming agent dissolves or leaches from
the coat to form pores in the coat for the fluid to enter the core and
dissolve
the active ingredient.
As used herein the term pore includes an aperture, orifice, bore,
channel, hole, a discrete area of weakness or as created by soluble or
leachable materials.
-43-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Certain general illustrative examples of paste compositions and their
uses may be helpful in understanding the present invention and are itemized
as follows:
Item 1 is a timed, delayed or extended release liquid or semi-solid
matrix or magma or paste composition which is non-newtonian and composed
of one or more addictive substances and,
(i) one or more clays,
(ii) and/or one or more substances selected from polyacrylates,
starches, carbomers, cellulose ethers, cellulose esters, polysaccharide gums,
natural gums, fillers and poloxamers
(iii) admixed in oily, waxy or fatty substance or a combination
thereof
(iv) and particle size of non dissolved materials is less than 1000
microns
(v) and administered in a capsule or dispensing device
Item 2 is a timed, delayed or extended release liquid or semi-solid
matrix or magma or paste composition which is non-newtonian and composed
of one or more addictive substances and,
(i) one or more clays,
(ii) and/or one or more substances selected from polyacrylates,
starches, carbomers, cellulose ethers, cellulose esters, polysaccharide gums,
natural gums, fillers and poloxamers
(iii) admixed in an aqueous vehicle
(iv) and particle size of non dissolved materials is less than 1000
microns
(v) and administered in a capsule or dispensing device.
Item 3 is a timed, delayed or extended release liquid or semi-solid
matrix or magma or paste composition which is non-newtonian and composed
of one or more addictive substances and,
(i) one or more clays,
-44-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
(ii) and/or one or more substances selected from polyacrylates,
starches, carbomers, cellulose ethers, cellulose esters, polysaccharide gums,
natural gums, fillers and poloxamers
(iii) admixed in a vehicle which is made by combining water and one
or more of oily, waxy and fatty substance
(iv) and particle size of non dissolved materials is less than 1000
microns
(v) and administered in a capsule or dispensing device
Item 4 is the composition according to items 1, 2 or 3 which contains
one or more surfactant.
Item 5 is the composition according to items 1, 2 or 3 which contains
one or more disintegrants.
Item 6 is the composition according to items 1, 2 or 3 which contains
one or more medium chain triglycerides or their esters.
Item 7 is the composition according to items 1, 2 or 3 which contains d-
alpha-tocopheryl polyethylene glycol 1000 succinate and or glyceryl
monostearate and or soy polysaccharides.
Item 8 is the composition according to items 1, 2 or 3 in which the clay
is bentonite.
Item 9 is the composition according to items 1, 2 or 3 in which the clay
is montmorillonite.
Item 10 is the composition according to items 1, 2 or 3 in which the clay
is Pascalite.
Item 11 is the composition according to items 1, 2 or 3 in which the clay
is Smectite, illite, sepiolite, palygorskite, muscovite, allevardite, amesite,
hectorite, fluorohectorite, saponite, beidellite, talc, nontronite,
stevensite,
mica, vermiculite, fluorovermiculite, halloysite and fluorine-containing
synthetic types of mica, phyllosilicates, beidellite; volkonskoite; hectorite;
sauconite; sobockite; svinfordite; and the like, mixed illite/smectite
minerals,
such as rectorite, tarosovite, Iedikite and admixtures of illites with the
clay
minerals named above.
-45-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 12 is the composition according to items 1, 2 or 3 which contains
one or more stabilizer.
Item 13 is the composition according to items 1, 2 or 3 which contains
one or more anti-oxidant.
Item 14 is the composition according to items 1, 2 or 3 which contains
one or more anti-foaming substance.
Item 15 is the composition according to items 1, 2 or 3 which contains
inorganic or organic bases.
Item 16 is the composition according to items 1, 2 or 3 which contains
salts or electrolytes.
Item 17 is the composition according to items 1, 2 or 3 in which the clay
is less than 95% by weight.
Item 18 is the composition according to items 1, 2 or 3 in which the clay
is less than 5% by weight.
Item 19 is the composition according to items 1, 2 or 3 in which the clay
is from about 5% to about 20% by weight.
Item 20 is the composition according to items 1, 2 or 3 in which the clay
is from about 20% to about 40% by weight.
Item 21 is the composition according to items 1, 2 or 3 in which the clay
is from about 30% to about 60% by weight.
Item 22 is the composition according to items 1, 2 or 3 in which the
internal and or external surface of the capsule is coated with a pH sensitive
film coat.
Item 23 is the composition according to items 1, 2 or 3 in which the
internal and or external surface of the capsule is coated with a non pH
sensitive film coat.
Item 24 is the composition according to items 1, 2 or 3 in which the
capsule is a hard gelatin capsule or is made of a metal or alloy of metals
from
the periodic table, cellulose ether, vegetable or animal origin.
Item 25 is a liquid or semi-solid, matrix or magma or paste composition
which is non-newtonian, thixotropic and/or pseudoplastic and contains one or
-46-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
more clays or one or more controlled release polymeric agent for timed or
extended release of addictive substances.
Item 26 is the composition according to item 25 which contains one or
more surfactants.
Item 27 is the composition according to item 25 which contains one or
more super disintegrants.
Item 28 is the composition according to item 25 which contains one or
more medium chain triglycerides or their esters.
Item 29 is the composition according to item 25 which contains
d-alpha-tocopheryl polyethylene glycol 1000 succinate and or glyceryl
monostearate and or soy polysaccharides.
Item 30 is the composition according to item 25 in which the clay is
bentonite.
Item 31 is the composition according to item 25 in which the clay is a
montmorillonite.
Item 32 is the composition according to item 25 in which the clay is
Pascalite.
Item 33 is the composition according to item 25 in which the clay is
Smectite, illite, sepiolite, palygorskite, muscovite, allevardite, amesite,
hectorite, fluorohectorite, saponite, beidellite, talc, nontronite,
stevensite,
mica, vermiculite, fluorovermiculite, halloysite and fluorine-containing
synthetic types of mica, phyllosilicates, beidellite; volkonskoite; hectorite;
sauconite; sobockite; svinfordite; and the like, mixed illite/smectite
minerals,
such as rectorite, tarosovite, ledikite and admixtures of illites with the
clay
minerals named above.
Item 34 is the composition according to item 25 which contains one or
more stabilizer.
Item 35 is the composition according to item 25 which contains one or
more anti-oxidant.
Item 36 is the composition according to item 25 which contains one or
more anti-foaming substance.
-47-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 37 is the composition according to item 25 which contains
inorganic or organic bases.
Item 38 is the composition according to items 1, 2, 3 or 25 which
makes it harder to abuse addictive substances.
Item 39 is the composition according to items 1, 2, 3 or 25 which
discourages drug abuse by at least one of the modes of crushing, milling or
grinding the dosage form to powder and snorting or inhalation by the nasal
route or dissolving for abuse via the parenteral route.
Item 40 is the composition of items 1, 2, 3, or 25 which contains
materials selected from ethylene-vinyl acetate polymers, carbomers, cellulose
ethers, esters, stearates, cellulose derivatives, acyl substituted cellulose
acetates and derivatives thereof, polyurethanes, polystyrenes, polyvinyl
chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated
polyolefins, and polyethylene oxide, polyethylene, polyvinyl pyrrolidone,
ethylene vinylacetate, polyethylene glycol, cellulose acetate butyrate and
cellulose acetate propionate.
Item 41 is the composition of items 1, 2, 3, or 25 which contains
sucrose acetate isobutyrate.
Item 42 is the composition according to item 25 in which the internal
and/or external surface of the capsule is coated with a pH sensitive film
coat.
Item 43 is the composition according to item 25 in which the internal
and/or external surface of the capsule is coated with a non pH sensitive film
coat.
Item 44 is the composition according to items 1, 2, 3, or 25 wherein the
addictive substance is a drug, prodrug or their salts, bases, intermediates,
enantiomers, polymorphs, derivatives, and metabolites or a combination
thereof.
Item 45 is the composition according to items 1, 2, 3, or 25 wherein the
addictive substance is a narcotic analgesic.
Item 46 is the composition according to items 1, 2, 3, or 25 which
contains a poly(lactide).
-48-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 47 is the composition according to items 1, 2, 3, or 25 which
contains a poly(lactide-coglycolide).
Item 48 is the composition of items 1, 2, 3, or 25 which contains a
poly(glycolide).
Item 49 is the composition of items 1, 2, 3, or 25 which contains a
poly(caprolactone).
Item 50 is the composition of items 1, 2, 3, or 25 which contains an
oxidized cellulose.
Item 51 is the composition of items 1, 2, 3, or 25 which contains a
poly(D,L-lactic acid).
Item 52 is the composition of items 1, 2, 3, or 25 which contains a
nonbiodegradable polymer.
Item 53 is the composition of items 1, 2, 3, or 25 which contains a
biodegradable polymer.
Item 54 is the composition of items 1, 2, 3, or 25 suitable for rectal
administration.
Item 55 is the composition of items 1, 2, 3, or 25 suitable for oral
administration.
Item 56 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of controlled release compositions having
different release rates; and
(b) administering the compositions to the host in a capsule or patch.
Item 57 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the step of administering the composition to the
host
topically on the skin.
Item 58 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the step of administering the composition to the
host
via injection.
Item 59 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
-49-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
(a) providing an amount of a controlled release composition and
another amount of a composition having different release rates; and
(b) administering the compositions to the host in a capsule or patch.
Item 60 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of an immediate release composition; and
(b) administering the compositions to the host in a capsule or patch.
Item 61 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a composition a having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch.
Item 62 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a immediate release composition; and
(b) administering the compositions to the host in the same capsule
or patch.
Item 63 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a composition having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein the two compositions contain the same or different
drugs.
Item 64 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a immediate release composition; and
-50-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein the two compositions contain the same or different
drugs.
Item 65 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a composition having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein one composition contain an opiod drug and the other a
non opiod drug.
Item 66 is a method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a immediate release composition; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein one composition contain an opiod drug and the other a
non opiod drug.
Item 67 is the composition of items 1, 2, 3, or 25, wherein the
composition is prepared with out having to go through a heating process.
Item 68 is the composition of items 1, 2, 3, or 25, wherein the
composition is encapsulated within a microsphere or microcapsule.
Item 69 is the composition of items 1, 2, 3, or 25, wherein the
composition is lyophilized.
Item 70 is the composition of items 1, 2, 3, or 25, wherein the
controlled release formulation is associated with inert pharmaceutical
excipients, said excipients optionally processed into spheres or other shapes
and incorporated into a dosage form.
Item 71 is the method for the administration of the composition of items
1, 2, 3, or 25, comprising the steps of
-51 -
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
(a) providing an amount of a controlled release composition and
another
amount of a composition having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein one composition contain an opiod agonist and the other
a opiod antagonist.
Item 72 is the composition of items 1, 2, 3, or 25 which contains
sweetening agents.
Item 73 is the composition of items 1, 2, 3, or 25 which contains
coloring agents.
Item 74 is the composition of items 1, 2, 3, or 25, administered for
pediatric use.
Item 75 is the composition of items 1, 2, 3, or 25 which is dried.
Item 76 is the composition of items 1, 2, 3, or 25 wherein the addictive
substance is an opioid agonist selected from the group consisting of
alfentanil,
allyiprodine, alphaprodine, anileridine, benzylmorphine, bezitramide,
buprenorphine, butorphanol, clonitazene, codeine, desomorphine,
dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine,
dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene,
dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine,
ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine,
dihydroetorphine, fentanyl hydrocodone, hydromorphone, hydroxypethidine,
isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil,
meperidine, meptazinol, metazocine, methadone, metopon, morphine,
myrophine, narceine, nicomorphine, norlevorphanol, normethadone,
nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone,
oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan,
phenazocine, phenoperidine, piminodine, piritramide, propheptazine,
promedol, properidine, propoxyphene, sufentanil, tilidine, alphaprodine,
dextroporpoxyphene, propiram, profadol, phenampromide, thiambutene,
pholcodeine , 3-trans-dimethylamino-4-phenyl-4-trans-carbethoxy-delta'-
-52-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
cyclohexene, 3- dimethylamino-0-(4-methoxyphenylcarbamoyl )-
propiophenone oxime, (- ).beta.-2'-hydroxy-2,9-dimethy1-5-phenyl-6,7-
benzomorphan, (-)2'-hydroxy-2- (3-methyl-2-butenyl)-9-methyl-5-phenyl-6,7-
benzomorphan, pirinitramide, (- ).alpha.-5,9-diethyl-2'-hydroxy-2-methyl-6,7-
benzomorphan, ethyl 1-(2- dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-
4-oxo-6-phenylindole- 2- carboxylate, 1 -B enzoylmethyl -2,3-dimethyl -3-(m-
hydroxyphenyl)-piperidine, N-allyl-7.alpha.-(l-(R)-hydroxy-l-methylbutyl )-
6,14-endo-ethanotetrahydron ororipavine, (-)T-hydroxy-2-methyl-6,7-
benzomorphan, noracylmethadol, phenoperidine, .alpha.-dl-methadol, .beta.-
dl-methadol, .alpha.-l-methadol (2-15 mg.), .beta.-dl-acetylmethadol, .alpha.-
1-acetylmethadol and .beta.-l- acetylmethadol; or pharmaceutically
acceptable salts thereof, stereoisomers thereof, ethers thereof, esters
thereof,
or mixtures thereof.
Item 77 is the composition according to items 1, 2, 3 or 25 wherein the
composition is prepared by blending or homogenizing the components in the
composition into a uniform non setting paste in a non volatile vehicle.
Item 78 is a liquid or semi-solid matrix or magma or paste composition,
composed of one or more controlled release agent, and/or one or more clays
such as bentonite and one or more addictive substance in a non aqueous
vehicle, selected from waxes, Arachis oil, Castor oil, Cottonseed oil, Maize
(corn) oil, Olive oil, palm oil, Sesame oil, Soybean oil and Sunflower oil and
optionally materials selected from disintegrants, semi-solid or solid
lipophilic
vehicles, adsorption enhancers humectants, surfactants and stabilizers;
wherein the physicochemical properties of the composition makes it harder to
abuse the addictive substance and discourages drug abuse by at least one of
the modes of crushing, milling or grinding the dosage form to powder or
heating the dosage form to vapour and snorting or inhalation by the nasal
route or dissolving to abuse via the parenteral route.
Item 79 is a liquid or semi-solid matrix or magma or paste composition,
composed of one or more controlled release agent and one or more addictive
substance in a non aqueous vehicle, selected from waxes, Arachis oil, Castor
oil, Cottonseed oil, Maize (corn) oil, Olive oil, palm oil, Sesame oil,
Soybean
-53-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
oil and Sunflower oil and optionally materials selected from disintegrants,
semi-solid or solid lipophilic vehicles, adsorption enhancers humectants,
surfactants and stabilizers encapsulated in a gelatin capsule which is coated
with a delayed release or controlled release film coat; wherein the
physicochemical properties of the composition makes it harder to abuse the
addictive substance and discourages drug abuse by at least one of the modes
of crushing, milling or grinding the dosage form to powder or heating the
dosage form to vapour and snorting or inhalation by the nasal route or
dissolving to abuse via the parenteral route.
Item 80 is the composition of items 1, 2, 3, 25, 78, or 79 which allows
once daily dosing of the narcotic analgesic.
Item 81 is the composition of items 1, 2, 3, 25, 78, or 79 which allows
for peak plasma concentration(s) to occur between 3 to 14 hours after dosing
of the narcotic analgesic.
Item 82 is the composition of items 1, 2, 3, 25, 78, or 79 which in the
presence of alcohol does not dose dump.
Item 83 is the composition of items 1, 2, 3, 25, 78, or 79 which is
coated with a film coat and wherein in the presence of alcohol does not dose
dump.
Item 84 is the composition of items 1, 2, 3, 25, 78, or 79 which is
coated with a film coat containing cellulose esters or polymethacrylates or
polyethylene glycol or cellulose ethers, esters or a combination wherein in
the
presence of alcohol does not dose dump.
Item 85 is a liquid or semi-solid matrix or magma or paste composition,
composed of one or more controlled release agent and one or more addictive
substance which is coated with polymeric and or non polymeric materials
selected from a pH sensitive or non pH sensitive or semi-permeable polymers
or a combination wherein in the presence of alcohol does not dose dump.
Item 86 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a composition having different release rates; and
-54-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
(b) administering the compositions to the host in a capsule or patch;
(c) in which there is no dose dumping in the presence of alcohol
Item 87 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of an immediate release composition; and
(b) administering the compositions to the host in a capsule or patch;
(c) in which there is no dose dumping in the presence,of alcohol
Item 88 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a composition a having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) in which there is no dose dumping in the presence of alcohol
Item 89 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a immediate release composition; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) in which there is no dose dumping in the presence of alcohol.
Item 90 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another
amount of a composition having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein the two compositions contain the same or different
drugs; and
(d) there is no dose dumping in the presence of alcohol
-55-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 91 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a immediate release composition; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein the two compositions contain the same or different
drugs; and
(d) in which there is no dose dumping in the presence of alcohol
Item 92 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another amount of a composition having different release rates; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein one composition contain an opiod drug and the other a
non opiod drug; and
(d) in which there is no dose dumping in the presence of alcohol
Item 93 is a method for the administration of the composition of items
1, 2, 3, 25, 78, or 79 comprising the steps of
(a) providing an amount of a controlled release composition and
another
amount of a immediate release composition; and
(b) administering the compositions to the host in the same capsule
or patch;
(c) wherein one composition contain an opiod drug and the other a
non opiod drug; and
(d) in which there is no dose dumping in the presence of alcohol
Item 94 is a paste composition comprising an addictive substance and
a nasal irritants.
Item 95 is a paste composition comprising a pharmaceutical active
substance and one or more materials selected from the group consisting of
-56-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
clays, controlled release agents, oily, waxy, and fatty substances for
preventing dose dumping in the presence of alcohol.
Item 96 is the composition of items 1, 2, 3, 25, 78, or 79 which provides
zero order release, first order or pseudo-first order release of drug content.
Item 97 is the composition of items 1, 2, 3, 25, 78, or 79 which releases
less than 60% of drug in 1 hour using USP basket dissolution apparatus 50
rpm.
Item 98 is the composition of items 1, 2, 3, 25, 78, or 79 which releases
less than 40% of drug in 1 hour using USP basket dissolution apparatus 50
rpm.
Item 99 is the composition of items 1, 2, 3, 25, 78, or 79 which releases
less than 20% of drug in 1 hour using USP basket dissolution apparatus at 50
rpm.
Item 100 is the composition of items 1, 2, 3, 25, 78, or 79 which
provides pulsed delivery.
Item 101 is the composition of items 1, 2, 3, 25, 78, or 79 which
provides chronotherapeutic delivery.
Item 102 is a composition comprising an active substance and
materials selected from the group clays, controlled release agents, oily,
waxy,
and fatty substances for preventing dose dumping in the presence of alcohol
and which makes it difficult for drug abuse.
Item 103 is a composition comprising an active substances in oily,
waxy, and fatty substances and optionally materials selected from the group
clays, controlled release agents for preventing dose dumping in the presence
of alcohol and or which makes it difficult for drug abuse.
Item 104 is the composition according to items 1, 2, 3, 25, 77, 78, 79,
95, 102 or 103 which is presented as tablet, pellet, bead, microsphere,
nanoparticle or granules
Item 105 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 for pediatric use.
Item 106 is the composition according to items 1, 2, 3, 25, 78, 79,
95,102 or 103 for use as an implant or subcutaneous application.
-57-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 107 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein dissolution using a USP dissolution tester is not
significantly affected by the rotation speed of the basket or paddle in the
speed range from about 25 rpm to about 150 rpm.
Item 108 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein dissolution using a USP dissolution tester is not
significantly affected by the rotation speed of the basket or paddle in the
speed range from about 50 rpm to about 150 rpm.
Item 109 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein dissolution using a USP dissolution tester is not
significantly affected by the rotation speed of the basket or paddle in the
speed range from about 50 rpm to about 100 rpm.
Item 110 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein dissolution using a USP dissolution tester is not
significantly affected by the rotation speed of the basket or paddle in the
speed range from about 50 rpm to about 75 rpm.
Item 111 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly in alcoholic media.
Item 112 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly at 50 rpm in about I% to
about 10% alcoholic media.
Item 113 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly at 50 rpm in about 10% to
about 20% alcoholic media.
Item 114 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly at 50 rpm in about 20% to
about 30% alcoholic media.
-58-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 115 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly at 50 rpm in about 30% to
about 40% alcoholic media.
Item 116 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly at 50 rpm in about 40% to
about 50% alcoholic media.
Item 117 is the composition according to items 1, 2, 3, 25, 78, 79, 95,
102 or 103 wherein there is no dose dumping during dissolution using a USP
dissolution tester with basket or paddle assembly at 50 rpm in about 50% to
about 70% alcoholic media.
Item 118 is the composition according to items 1, 2, 3, 25, 78, or 79,
wherein the addictive substance is an opiod agonist or narcotic analgesic or
abuse-able substance or euphoric analgesic.
Item 119 is the composition according to items 95, 102, or 103,
wherein the active substance is susceptible to abuse or is known to be
addictive.
Item 120 is a use of the composition of any one of items 1, 2, 3, 25, 78,
or 79 for treatment of addiction to an addictive substance.
Item 121 is a use of the composition of any one of items 1, 2, 3, 25, 78,
or 79 for reducing dose dumping of the addictive substance.
Item 122 is a use of the composition of any one of items 1, 2, 3, 25, 78,
or 79 for reducing the abuse potential of the addictive substance for at least
one of the modes of crushing, milling or grinding the dosage form to powder
and snorting or inhalation by the nasal route or dissolving for abuse via the
parenteral route.
Item 123 is a method for reducing abuse of an addictive substance by
a subject in need of treatment by the addictive substance comprising,
administering the composition of any one of items 1, 2, 3, 25, 78, or 79,
comprising a therapeutically effective amount of the addictive substance, to
the subject.
-59-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Item 124 is the method of item 61, wherein the abuse comprises dose
dumping.
Item 125 is a method for treating addiction to an addictive substance in
a subject comprising, administering the composition of any one of items 1, 2,
3, 25, 78, or 79, comprising a therapeutically effective amount of the
addictive
substance or a derivative thereof, to the subject.
Item 126 is the method of items 65, 66, or 71 where the opioid agonist
is selected from the group consisting of alfentanil, allylprodine,
alphaprodine,
anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol,
clonitazene, codeine, desomorphine, dextromoramide, dezocine,
diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol,
dimepheptanol, dimethyithiambutene, dioxaphetyl butyrate, dipipanone,
eptazocine, ethoheptazine, ethylmethyithiambutene, ethylmorphine,
etonitazene, etorphine, dihydroetorphine, fentanyl hydrocodone,
hydromorphone, hydroxypethidine, isomethadone, ketobemidone,
levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol,
metazocine, methadone, metopon, morphine, myrophine, narceine,
nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene,
normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum,
pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine,
piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene,
sufentanil, tilidine, alphaprodine, dextroporpoxyphene, propiram, profadol,
phenampromide, thiambutene, pholcodeine , 3-trans-dimethylamino-4-
phenyl-4-trans-carbethoxy-delta'-cyclohexene, 3- dimethylamino-0-(4-
methoxyphenylcarbamoyl)-propiophenone oxime, (- ).beta.-2'-hydroxy-2,9-
dimethyl -5-phenyl -6,7-benzomorphan, (-)2'-hydroxy-2- (3-methyl -2-
butenyl)-9-methyl-5-phenyl-6,7-benzomorphan, pirinitramide, (- ).alpha.-5,9-
d iethyl -2'-hydroxy-2-methyl -6,7-benzomorphan, ethyl 1-(2-
dimethyl aminoethyl)-4, 5,6,7-tetrahydro-3-methyl -4-oxo-6-phenylindole- 2-
carboxylate, 1 -B enzoylmethyl-2,3-dimethyl-3-(m-hydroxyphenyl)-
piperidine, N-allyl -7.alpha.-(1-(R)-hydroxy-l-methylbutyl )-6,14-endo-
ethanotetrahydron ororipavine, (-)T-hydroxy-2-methyl-6,7-benzomorphan,
-60-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
noracylmethadol, phenoperidine, .alpha.-dl-methadol, beta. -d 1-methado 1,
.alpha.-1-methadol (2-15 mg.), .beta.-dI-acetylmethadol, .alpha.-1-
acetylmethadol and .beta.-1- acetylmethadol; or pharmaceutically acceptable
salts thereof, stereoisomers thereof, ethers thereof, esters thereof, or
mixtures
thereof.
When introducing elements disclosed herein, the articles "a", "an",
"the", and "said" are intended to mean that there are one or more of the
elements unless the context dictates otherwise. For example, the term "a
compound" and "at least one compound" may include a plurality of
compounds, including mixtures thereof. The terms "comprising", "having",
"including" are intended to be open-ended and mean that there may be
additional elements other than the listed elements.
The above disclosure generally describes the present invention. A
more complete understanding can be obtained by reference to the following
specific Examples. The Examples are described solely for purposes of
illustration and are not intended to limit the scope of the invention. Changes
in form and substitution of equivalents are contemplated as circumstances
may suggest or render expedient. Although specific terms have been
employed herein, such terms are intended in a descriptive sense and not for
purposes of limitation.
-61 -
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
EXAMPLES
EXAMPLE 1
Extended release Oxycodone (abuse prevention capsules)
Component Amount (%w/w)
xycodone 20
Corn Oil 50
arbopol 971 8
Hydroxypropylmethyl cellulose 22
METHOCELTM KIOOM Premium)
The samples were prepared:
1. Weigh corn oil in a glass beaker and immerse Silverson high shear
mixer fitted with a homogenizing head into the oil.
2. Gradually add carbopol followed by hydroxypropylmethyl cellulose
while stirring vigorously until a homogeneous blend is observed.
3. Add oxycodone gradually while stirring vigorously until a homogeneous
blend is observed.
4. The result is a semi-solid or paste which can be filled into hard gelatin
capsules without "stringing".
5. Take samples from top, middle and bottom to determine potency and
homogeneity of the mix.
6. Fill into hard gelatin capsules.
7. Capsules are tested in a dissolution apparatus in varying
concentrations of alcohol with results shown in Figure 1. Method: 50 rpm, 10
mm cell, paddle/JP sinker wavelenght 280 nm. Medium: DI Water or Alcohol
and DI Water. Run Mode: 24 hours, sampling every hour.
-62-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
EXAMPLE 2
Extended release Oxycodone (abuse prevention capsules)
Component Amount (%w/w)
xycodone 20
orn Oil 49
arbopol 971 8
Bentonite 1
Hydroxypropylmethyl cellulose 22
METHOCELTM K100M Premium)
The samples were prepared:
1. Weigh corn oil in a glass beaker and immerse Silverson high shear
mixer fitted with a homogenizing head into the oil.
2. Gradually add bentonite, carbopol and hydroxypropylmethyl cellulose
while stirring vigorously until a homogeneous blend is observed.
3. Add oxycodone gradually while stirring vigorously until a homogeneous
blend is observed.
4. The result is a semi-solid or paste which can be filled into hard gelatin
capsules without "stringing".
5. Take samples from top, middle and bottom to determine potency and
homogeneity of the mix.
6. Fill into hard gelatin capsules.
-63-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
EXAMPLE 3
Extended release Oxycodone (abuse prevention capsules)
Component Amount (%w/w)
Oxycodone 26
Corn Oil 49
Sucrose acetate isobutyrate 2
Bentonite I
Hydroxypropylmethyl cellulose 22
(METHOCELTM K100M Premium)
The samples were prepared:
1. Weigh Sucrose acetate isobutyrate and place in a glass beaker. Place
beaker on a hot plate and heat until the Sucrose acetate isobutyrate becomes
molten. Immerse Silverson high shear mixer fitted with a homogenizing head
into the molten liquid and gradually add the oil under high shear.
2. Gradually add bentonite, and hydroxypropylmethyl cellulose while
stirring vigorously until a homogeneous blend is observed.
3. Add oxycodone gradually while stirring vigorously until a homogeneous
blend is observed.
4. The result is a semi-solid or paste which can be filled into hard gelatin
capsules without "stringing".
5. Take samples from top, middle and bottom to determine potency and
homogeneity of the mix.
6. Fill into hard gelatin capsules.
-64-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
EXAMPLE 4
Extended release Oxycodone (abuse prevention capsules)
Component Amount (%w/w)
Oxycodone 26
Cotton seed oil 45
Carbopol 934 5
Bees Wax 3
Bentonite 1
Hydroxypropylmethyl cellulose 20
(METHOCELTM K100M Premium)
The samples were prepared:
1. Weigh Bees Wax and place in a glass beaker. Place beaker on a hot
plate and heat until the Bees Wax becomes molten. Immerse Silverson high
shear mixer fitted with a homogenizing head into the molten liquid and
gradually add the oil under high shear.
2. Gradually add bentonite, carbopol and hydroxypropylmethyl cellulose
while stirring vigorously until a homogeneous blend is observed.
3. Add oxycodone gradually while stirring vigorously until a homogeneous
blend is observed.
4. The result is a semi-solid or paste which can be filled into hard gelatin
capsules without "stringing".
5. Take samples from top, middle and bottom to determine potency and
homogeneity of the mix.
6. Fill into hard gelatin capsules.
-65-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
EXAMPLE 5
Extended release Oxycodone (abuse prevention capsules)
Component Amount (%w/w)
Oxycodone 26
Castor oil 45
Carbopol 934 5.5
Polyethylene Glycol 8000 5
Bentonite 2.5
Polyethylene Oxide WSR-303 16
The samples were prepared:
1. Weigh polyethylene glycol and place in a glass beaker. Place beaker
on a hot plate and heat until the polyethylene glycol becomes molten.
Immerse Silverson high shear mixer fitted with a homogenizing head into the
molten liquid and gradually add the oil under high shear.
2. Gradually add bentonite, carbopol and polyethylene oxide while stirring
vigorously until a homogeneous blend is observed.
3. Add oxycodone gradually while stirring vigorously until a homogeneous
blend is observed.
4. The result is a semi-solid or paste which can be filled into hard gelatin
capsules without "stringing".
5. Take samples from top, middle and bottom to determine potency and
homogeneity of the mix.
6. Fill into hard gelatin capsules.
-66-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
EXAMPLE 6
Extended release Oxycodone (abuse prevention capsules)
Component Amount (%w/w)
Oxycodone 25
Corn oil 40
Carbopol 934 8
Sodium lauryl sulphate 10
Hydroxypropylmethyl cellulose 18
(METHOCELTM K100M Premium)
The samples were prepared:
1. Weigh the oil in a glass beaker. Immerse Silverson high shear mixer
fitted with a homogenizing head into the oil.
2. Gradually add carbopol and hydroxypropylmethyl cellulose while
stirring vigorously until a homogeneous blend is observed.
3. Add oxycodone gradually while stirring vigorously until a homogeneous
blend is observed.
4. The result is a semi-solid or paste which can be filled into hard gelatin
capsules without "stringing".
5. Take samples from top, middle and bottom to determine potency and
homogeneity of the mix.
6. Fill into hard gelatin capsules.
-67-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Example 7
Combination Extended release Oxycodone + Immediate release Tramadol
(abuse prevention capsules)
(i) Preparation of immediate release tramadol paste (Preparation 1)
Component Amount (%w/w)
Tramadol 25
Corn oil 40
Starch 1500 8
Crospovidone 5
Hydroxypropylmethyl cellulose 18
(METHOCELTM E5 Premium LV)
(ii) Preparation of controlled release Oxycodone paste (Preparation 2)
This is made as taught in Example 1.
(iii) Preparation of combination Extended release Oxycodone + Immediate
release Tramadol (Abuse prevention capsules)
Fill the required amount of preparation 1 into the hard gelatin capsule
followed by preparation 2. Seal the capsule. In another embodiment a
separation layer made of a wax such as carnuba wax or a high
molecular weight polyethylene glycol e.g., PEG 8000 may be filled into
the capsule to separate two or more preparations where
incompatibility or cross migration of components is of concern. In this
way several combinations of active sustances are possible.
-68-
CA 02626558 2008-04-18
WO 2007/131357 PCT/CA2007/000862
Example 8
Film coated Abuse prevention capsules.
This comprises film coating capsules made in Example 1 with a
polymethacrylate such as Eudragit L or S to impart a delayed or timed
release characteristics or lag phase.
Example 9
Film coated Abuse prevention capsules.
This comprises film coating capsules made in Example 1 with a cellulose
ether such as ethylcellulose alone or in combination with water soluble
polymers e.g., hydroxypropylmethyl cellulose.
Example 10
Film coated Abuse prevention capsules.
This comprises film coating capsules made in Example 1 with a
polymethacrylate such as Eudragit E to provide a protective sealing coat
or moisture barrier or improve mechanical properties.
-69-
